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Summary 
 
To analyze protein kinase B’s (PKB) effects on developmental and functional aspects of T 
cells, we have generated transgenic (tg) mouse lines expressing a constitutively active form of 
PKBa (myrPKB) in early stages of T cell development. Peripheral CD4+ T cells from 
myrPKB tg mice are hyper-reactive. They exhibit markedly higher proliferation upon 
suboptimal TCR ligation and are mostly independent of CD28-induced costimulatory signals. 
This becomes also evident in both, Th1 and Th2 cytokine production and cell cycle 
progression. 
 Interestingly, proliferation of myrPKB tg T cells is significantly resistant to the 
immunosuppressive agent cyclosporine A (CsA). CsA inhibits calcineurin activity and 
thereby negatively regulates NFAT signaling events by inhibiting its nuclear translocation. 
However, in the presence of CsA, myrPKB tg CD4+ T cells not only proliferate well, but are 
also able to produce cytokines shown to be dependent on NFAT activation. Thus, 
proliferation/cell division and cytokine production of myrPKB tg CD4+ T cells seems to be 
relatively independent of NFAT activity. 
 Analysis of nuclear and cytoplasmic extracts from unstimulated and TCR/CD3- 
stimulated myrPKB tg CD4+ T cells shows drastically reduced nuclear translocation of 
NFATc1 and NFATc2 proteins compared to wild type cells. A negative regulation, i.e. 
reduced nuclear accumulation, was also detected for NF-kBp65 and RelB, two members of 
the NF-kB transcription factor family. The negative regulation of nuclear accumulation of 
NFATs by myrPKB seems to result from a direct interaction of PKB with NFAT, as we could 
co-precipitate both molecules in immunoprecipitation assays. Thus, myrPKB could be 
involved in direct phosphorylation of NFATs and thereby inhibit its nuclear translocation. 
Inhibition of various known NFAT kinases, like JNK, ERK and p38 MAPK by 
pharmacological inhibitors did not reverse the negative regulation of NFAT in myrPKB tg 
CD4+ T cells, indicating that these kinases are not involved in this process. 
 To study whether the negative regulation of NFATs by myrPKB affects T cell 
development, we analyzed double transgenic mice expressing both, a constitutively active 
version of calcineurin (∆Cam) (which leads to strong NFAT activation) and myrPKB. ∆Cam 
tg mice have a severe block in thymocyte development at the DN3 stage. Compared to 
littermate controls ∆Cam tg mice show an almost complete absence of the DP population and 
on average a twenty five-fold reduction in thymic cellularity. Strikingly, in the ∆Cam/PKB 
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double tg mice this developmental block is significantly rescued with concomitant restoration 
of the DP population and cell numbers. ∆Cam DN3 cells lack icTCRb chain expression, 
which seems to be due to strongly diminished Rag1 protein expression. Expression of 
myrPKB in ∆Cam DN cells rescues Rag1 and icTCRb chain expression and restores ‘normal’ 
thymocyte development. However, expression of a pre-rearranged a/b TCR fails to overcome 
the severe block of differentiation in ∆Cam cells, although a partial rescue is obvious. This 
suggests that there are additional defects in ∆Cam DN cells, which are overcome by myrPKB.  
CsA treatment of neonatal thymic lobe cultures from ∆Cam mice restores normal 
thymocyte development, indicating involvement of NFATs as critical factors in the severe 
block in ∆Cam thymocyte development. Confocal studies clearly established that compared to 
∆Cam DN cells there is a significant reduction in the nuclear levels of NFATc1 as well as 
NFATc3 in ∆Cam/PKB cells. Downregulation of nuclear NFAT levels by myr PKB thus 
seems to be an essential parameter in ∆Cam cells to proceed with normal differentiation. 
In summary, the data from myrPKB tg peripheral CD4+ T cells and ∆Cam/PKB 
double tg thymocytes clearly establish PKB as an important modulator of T cell development 
and T cell function and PKB as a novel negative regulator of calcineurin/NFAT activation. 
This is further supported by the nuclear absence of NFAT proteins in myrPKB-induced T cell 
lymphoma. Indeed, shut-down of NFAT signalling by PKB may be an essential mechanism 
involved in PKB-induced tumorigenesis in the immune system in particular and in other 
systems in general. 
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Zusammenfassung 
 
Um die physiologische Rolle der PKB während der T-Zell-Reifung und –Aktivierung 
untersuchen zu können, analysierten wir transgene Mausstämme, die eine konstitutiv-aktive 
Form der PKBa (myrPKB) T-Zell-spezifisch exprimieren (myrPKB-tg Mäuse). Periphere 
CD4+ T-Zellen von myrPKB-tg Mäusen verhalten sich hyperreaktiv. Sie zeigten bereits sehr 
starke Proliferation nach minimaler TZR-Stimulation und waren weitgehend unabhängig von 
Kostimulation durch CD28, und zwar nicht nur in Bezug auf Zellprolifertation und 
Zellzyklusprogression, sondern auch hinsichtlich der Polarisation in Th1 und Th2 Zellen. 
Interessanterweise wiesen myrPKB-tg T-Zellen eine deutliche Resistenz gegenüber 
dem Immunsuppressivum Cyclosporin A (CsA) auf. CsA inhibiert die Aktivierung von 
Calcineurin und verhindert dadurch die Translokation von NFAT in den Zellkern. Myr PKB- 
tg CD4+ T-Zellen proliferierten in Gegenwart von CsA und produzierten Zytokine, deren 
Synthese von der Aktivierung von NFAT abhängt. Proliferation, Zellteilung und 
Zytokinproduktion myr PKB-tg CD4+ T-Zellen sind also relativ unabhängig von der NFAT-
Aktivierung.  
Die Analyse von nukleären und zytoplasmatischen Extrakten aus unstimulierten und 
über den TZR-stimulierten myrPKB-tg CD4+ T-Zellen zeigte eine drastisch reduzierte 
nukleäre Translokation von NFATc1 und NFATc2 im Vergleich zu wildtypischen Zellen. 
Diese Form der negative Regulation fand sich nicht nur bei NFAT–Transkriptionsfaktoren, 
sondern auch bei NF-kB p65 und Rel B, wohingegen die Aktivierung von NF-kB p50 normal 
war. Die Inhibierung verschiedener Kinasen, die für die zelluläre Lokalisation von NFAT 
verantwortlich sind, wie JNK, ERK, p38 MAPK etc., durch pharmakologische Inhibitoren 
führte nicht zur Blockade der negativen Regulation von NFAT in myrPKB-tg CD4+ T-Zellen. 
Durchgeführte Ko-Immunpräzipitationen legen nahe, daß die negative Regulation von NFAT 
durch PKB wahrscheinlich durch direkte Interaktion der beiden Moleküle geschieht.   
 Um einen möglichen Einfluß der beschriebenen negativen Regulation der NFATs 
duch die aktivierte PKB auf die T-Zell-Entwicklung untersuchen zu können, analysierten wir 
doppelt tansgene Mäuse, die neben myr PKB eine konstitutiv aktive Form von Calcineurin 
(∆Cam) exprimieren. ∆Cam-tg Mäuse weisen eine schwere Störung der 
Thymozytendifferenzierung im Stadium der DN3-Zellen auf, was zu einem nahezu 
vollständigen Fehlen der DP-Population und einer ca. 25-fach reduzierten Zellzahl im 
Thymus führt. Zu unserer Überraschung, war diese Differenzierungsblockade in ∆Cam/PKB 
doppelt-tg Mäuse signifikant schwächer ausgeprägt, was sich auch in einem Wiederauftreten 
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der DP-Population manifestierte. Wir konnten zeigen, daß ∆Cam-DN3-Zellen keinen TZR 
exprimieren, was wahrscheinlich Folge einer nahezu vollständig fehlenden Expression des 
rag1 Gens ist. MyrPKB-Expression stellte die Expression von RAG1 und der TZRb-Kette in 
∆Cam-DN3-Zellen wieder her und erlaubte die weitere Differenzierung von DN3-Zellen zu 
DP-Zellen. Die Behandlung von thymischen Lobi neonataler ∆Cam Mäuse mit CsA in vitro 
hatte eine normale Thymozytendifferenzierung und normale Zellzahlen zur Folge. Somit 
scheinen NFAT-Proteine kritische Faktoren für die durch ∆Cam-induzierte Blockade der 
Thymozytendifferenzierung zu sein.  
 Mittels konfokaler Mikroskopie konnten wir eine signifikante Reduktion in der 
nukleären Lokalisation von NFATc1 und NFATc3 in ∆Cam/PKB-DN-Zellen im Vergleich zu 
∆Cam-DN-Zellen beobachten. Unsere Ergebnisse, die wir an myrPKB-tg peripheren CD4+ T-
Zellen und an ∆Cam/PKB doppelt-tg Thymozyten gewonnen haben, legen nahe, daß die 
aktive Form der PKB die Anreicherung von NFAT Proteinen im Kern negativ beeinflussen 
kann. Dieses Konzept wird ferner durch das Fehlen von NFATc1 und c2 in myrPKB 
induzierten T-Zell-Lymphomen und durch Kinase-Aktivitäts-Asssays gestützt, die deutlich 
zeigten, daß NFAT von PKB in vitro phophoryliert werden kann.  
Unsere Daten deuten auf eine Schlüsselstellung der PKB bei der Modulation der T-
Zell-Aktivierung, der Proliferation und der Modulation von T-Zell-Effektorfunktionen hin. 
Insbesondere zeigen wir erstmals, daß NFAT ein Substrat der PKB ist. Diese Arbeit eröffnet 
somit neue Perspektiven für das bessere Verständnis derjenigen Mechanismen, die der PKB-
induzierten Tumorigenese im Immunsystem und in anderen Organsystemen zugrunde liegen.   
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1. Introduction 
 
1.1 The Immune System: An Overview 
 
The immune system is an organism’s inherent remarkable defense mechanism against all kind 
of infections. It provides the means to make rapid, specific, and protective responses against 
the myriad potentially pathogenic microorganisms that inhabit in our surrounding. Though, 
with evolution the complexity of the immune system has increased many fold in the higher 
vertebrates, the basic purpose of it remains unaltered i.e., to provide protection against any 
kind of pathogenic agent, both internal and external.  
1.1.1 Cells of the immune system 
 
The immune system consists of a wide range of distinct cell types. These include 
lymphocytes, the central players in determining the specificity of immune response, dendritic 
cells (DCs), Langerhans cells, monocytes/macrophages, natural killer (NK) cells, neutrophils, 
mast cells, basophils and eosinophils.  
 Lymphocytes differ from each other, both in their epitope specificity and functions. 
Functionally lymphocytes are divided into two broad classes: the B-lymphocytes, the 
antibody secreting cells and the T-lymphocytes. T-lymphocytes are involved in important 
helper functions and direct effector functions. Specialized T-lymphocytes (regulatory T cells) 
have the capacity to suppress specific immune responses. 
T-Lymphocytes 
Development and differentiation of T lymphocytes take place in the thymus. Based on their 
cell surface receptors T cells can be divided into two categories, the ab T cell receptor (TCR) 
bearing T cells and the gd TCR bearing T cells. ab T cells comprise of two important sub-
lineages: cells that express the CD4 co-receptor (CD4+ T cells) and those that express CD8 
(CD8+ T cells). Upon priming with antigen, naive CD4+ T cells differentiate into cells that 
primarily secrete the cytokines IL-4, IL-13, IL-5, IL6 and IL-10 (Th2 cells) or into cells that 
mainly produce IL2, IFN-g and lymphotoxin (Th1 cells). Th2 cells are very effective in 
helping B cells to develop into antibody-producing cells, whereas Th1 cells are effective 
inducers of cellular immune responses, involving enhancement in the microbicidal activity of 
macrophages and consequent increased efficiency in lysing microorganisms. CD8+ T cells, 
upon antigen encounter develop into cytotoxic T-lymphocytes (CTLs) capable of efficiently 
lysing target cells that express their specific antigens.  
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Antigen recognition by the TCR requires processing of the antigen and presentation of the 
processed antigen in the context of major histocompatibility (MHC) molecules. CD4+ T cells 
recognize antigens/peptides in the context of MHC II, whereas CD8+ T cells recognize 
antigen presented by MHC I molecules (1,2). MHC II molecules bind peptides derived from 
proteins that have been taken up by the APC through an endocytic process. Thus, CD4+ T 
cells are specialized to mainly recognize antigens derived from exogenous sources. In 
contrast, MHC I molecules are mainly loaded with peptides derived from internally 
synthesized proteins, including viral gene products. Thus, CD8+ T cells are specialized in 
recognizing antigens derived from endogenous sources. 
1.1.2 T cell activation 
The TCR is associated with a set of transmembrane proteins, collectively referred to as the 
CD3 complex, that play a critical role in TCR downstream signal transduction. The CD3 
complex consists of g, d and e chains and is associated with a homodimer of two z chains or a 
heterodimer of z and h chains (3,4). The cytosolic domains of CD3 g, d and e and of z and h, 
contain one or more copies of a signaling motif, the immunoreceptor tyrosine-based activation 
motif (ITAM) (5,6). These motifs are targets for tyrosine phosphorylation by protein tyrosine 
kinases, which are the key players in propagating the downstream signaling events. 
 Interaction of the TCR/CD3 complex with its specific peptide leads to the activation of 
a T cell. Among the earliest signaling events are, the activation of various tyrosine kinases (7-
9). Prominent among these early tyrosine kinases are the Src-family tyrosine kinases p56lck 
and p59fyn (10-17), which phosphorylate the ITAM motifs of the CD3 complex and ZAP-70, a 
Syk family tyrosine kinase (18-20), that binds to the phosphorylated ITAMs of the TCR z 
chains. The activation of these tyrosine kinases initiates a cascade of tyrosine phosphorylation 
of a series of substrates. These include (i) numbers of adaptor proteins that link the TCR to 
the Ras signaling pathway: (ii) Phospholipase Cg1, upon tyrosine phosphorylation its catalytic 
activity increases and thereby it enhanced ionositol phospholipids metabolism, leading to 
elevation of intracellular free calcium concentration and the activation of Protein kinase C 
(PKC); and (iii) an array of other important enzymes that control cellular growth and 
differentiation. The phosphorylation of LAT, an adaptor molecule, is of particular importance 
as it acts as an organizing scaffold to which a series of signaling intermediates bind and get 
activated to control the downstream signaling (21,22). 
 The TCR-ligand interactions on a T cell and an APC lead to structural rearrangements 
of various cell surface and cytosolic molecules on both cells to a complex structure known as 
the immunological synapse. Formation of the immunological synapse concentrates the key 
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signaling molecules to a very small but specialized region of the membrane, where it has been 
shown to strengthen and intensify the signaling events (23-25). Even though a T cell gets 
activated upon TCR/CD3 ligation, very often this leads to a response in which the cells 
become anergic, a state of unresponsiveness to a subsequent competent stimulus. For optimal 
T cell activation, in extra to TCR/CD3 ligation, the engagement of an accessory co-
stimulatory molecule is required. The engagement of CD28 on the T cell by CD80 (B7.1) 
and/or CD86 (B7.2) on the APC provides a potent co-stimulatory activity. Inhibition of this 
interaction both in vivo and in vitro shows diminished antigen-specific T cell-activation, 
indicating the physiological importance of CD80/CD86-CD28 interaction in T-cell activation 
(26,27).   
1.1.2 T cell functions 
 
T cells play important functions both in humoral and cell-mediated immunity. T cells provide 
help for B cells to develop into antibody producing cells, enhance the microbicidal capacity of 
monocytes and macrophages, inhibit certain types of immune responses, can directly kill 
target cells, and can mobilize inflammatory response. These effects significantly depend on 
their expression of specific cell-surface molecules and the secretion of cytokines. 
T cell mediated antibody response 
 T helper cells can induce B cells to make antibody responses to proteins and other T cell 
dependent antigens. Optimal B cell activation requires in addition to B cell receptor (BCR) 
ligation the engagement of CD40 with CD154 (CD40 L) on the T cell surface (28,29). This 
interaction is similar to that of CD28 co-stimulation in case of T cells.  
B-cell proliferation and immunoglobulin (Ig) secretion are enhanced by several type I 
cytokines including IL-2 and IL-4. Ig class switching is dependent on CD154/CD40 
interaction and is very often determined by T cell derived cytokines (30). The well studied 
example of this is the role of IL-4 in determining switching to IgG1 and IgE in mouse and 
IgG4 and IgE in human. 
Induction of cellular immunity  
 T cells also can enhance the pathogen clearance capabilities of monocytes and macrophages. 
IFN-g produced by T cells modulates the activity of these cells in generating nitric oxide and 
production of tumor necrosis factor (TNF), which these cells utilize to destroy intracellular 
bacteria and parasites. Th1-type cells are particularly effective in enhancing microbicidal 
action as they produce IFN-g. In contrast two major cytokines of Th2 cells, IL-4 and IL-10 
block these activities. Thus, Th2 cells often oppose the action of Th1 cells in inducing cellular 
immunity. 
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Cytotoxic T cells  
T cells, mainly CD8+ T cells can act as potent effector cells by directly killing target cells 
expressing specific antigens via cell-mediated cytotoxicity. Cytotoxicity is effected via two 
major mechanisms. One, via production of perforin and granzymes by the CTLs and the other 
by Fas and Fas ligand (Fas L) interaction (31,32).   
Cytokines 
Cytokines are a set of small molecular weight proteins, which mediate many important 
functions in the immune system. Cytokines can be divided into several classes: type I 
cytokines, includes hematopoietins (i.e., IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-11, IL-12, 
IL-13, IL-15, IL-21 and IL-23) as well as several hematopoietic growth factors. Type II 
cytokines include the interferons and IL-10, TNF related molecules including TNF, 
lymphotoxin and Fas ligand, Ig superfamily members comprising IL-1 and IL-18 and the 
chemokines, a growing family of molecules playing critical roles in a wide variety of immune 
and inflammatory functions. 
1.2 T Cell Development 
Development of T cells is initiated when common lymphoid progenitor cells (CLPs) from the 
fetal liver or bone marrow populate the thymic rudiment. Interactions with the thymic stroma 
induce these precursor cells to execute a highly ordered and precisely regulated T cell 
differentiation program. Along this developmental pathway T cell precursors are marked by 
sequential changes in expression of various differentiation antigens, such as CD4, CD8, 
CD44, and CD25, on the basis of which thymocytes can be classified into distinct subsets 
schematized in ascending order of maturity in Figure 1(A & B). The most immature T cell 
precursors are the CD4-CD8- double negative (DN) cells. The first major checkpoint that 
takes place during thymocyte differentiation ensures that only thymocytes that have generated 
a functional T cell receptor b (TCRb) chain, a process known as b-selection, become selected 
to differentiate to the CD4+CD8+ double positive (DP) stage (33,34). The second checkpoint 
occurs at the DP stage when thymocytes rearrange the TCRa chain and undergo positive and 
negative selection, as well as lineage commitment resulting in the differentiation of MHC 
restricted and self-tolerant CD4+ or CD8+ single positive (SP) ab-T cells (35). 
Murine DN thymocytes can be further subdivided into four distinct stages, depending 
on the gain or loss of expression of two surface molecules, CD44 and CD25 (36). The most 
immature DN subset is marked by CD44 expression (CD44+ CD25-, DN1), which has the 
potential to differentiate into multiple lineage cells like T-lymphocytes, B-lymphocytes, NK 
cells, and dendritic cells. This multi-potent T cell precursor upregulates surface expression of  
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Figure 1. Scheme of early T cell development (A) Cell development from less mature to more mature cells 
proceeds from left to right. Cell surface phenotype of each subpopulation is shown below it. Fluorescence 
intensity, as measured by flow cytometry on an arbitrary scale from negative (-) through low to very bright 
(+++), is indicated for each marker. (B) Selected molecules identified as critical regulators of selection 
checkpoints in T cell development. The function of most of these molecules was established by analysis of gene-
deficient mice. The molecules required for the DN3 to DN4 transition, may also be involved in positive and 
negative selection, but their function at the DP stage has not been evaluated. Molecules listed before the fork are 
 7 
required for both positive and negative selection. Molecules listed on far right adjust the threshold of thymic 
selection. (Figures partially adapted from Nat Rev Immunol. 2002;2:2-10 & Annu Rev Immunol. 2003;21:139-
76) 
 
 
CD25 and progresses to the CD44+CD25+ (DN2) stage. Progression of DN2 cells to the 
CD44-CD25+ (DN3) stage is dependent upon the stromally produced growth factor IL-7 and 
is accompanied by several events that are important in preparing the DN3 precursors for b-
selection. First, as CD25 expression is upregulated, the DN2 subpopulation undergoes 
proliferative expansion, second, accompanying down-modulation of CD44, DN3 cells lose 
their multipotency and become committed to the T lineage only. Third, c-kit (CD117) a 
receptor tyrosine kinase, whose expression closely parallels that of CD44, is down-regulated 
as the DN2 cells exit cell cycle, an event closely associated with initiation of gene 
rearrangement at the TCRb locus. DN3 cells down-regulate CD25 and progress to CD44-
CD25- (DN4) cells before transitioning into DP cells, where they undergo TCRa gene 
rearrangement and subsequent positive and negative selection to give rise to single positive T 
cells. 
1.2.1 V(D)J recombination 
The genetic rearrangement at the TCRb locus i.e., the fusion of three widely dispersed gene 
segments (V-variable, D- diversity, and J- joining) into a single coding unit takes place by a 
process termed Vb(Db)Jb recombination. This recombination at the TCRb locus is initiated at 
the CD44-CD25+, DN3 stage when the cis-acting TCRb enhancer opens the locus, making it 
accessible to the recombination machinery (37,38). During the recombination process double 
stranded DNA break is initiated at the boarders of the D and J gene elements by two site 
specific recombinases, Rag1 and Rag 2, following which the D and J elements are processed 
by the DNA repair enzyme DNA-dependent protein kinase (DNA-PK) and then fused 
together. This order of events is repeated in the joining of the Vb element to the newly formed 
DbJb element (39-41). 
1.2.2  b-selection and pre-TCR: the critical factors in early thymocyte 
development 
b-selection is a developmental checkpoint characterized by the formation of pre-TCR (pTCR) 
complex, which is a forerunner of the ab TCR complex (42). b-selected thymocytes 
successfully rearrange their TCRb gene segments and express a functional TCRb protein. The 
TCRb protein, in association with a 33 kD glycoprotein known as pre Ta chain forms the 
pTCR. 
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 Though structurally different, pTCR and mature TCR have functionally similar and 
dissimilar properties. Whereas signaling from both can induce proliferation, rescue from 
apoptosis, and expression of differentiation/activation genes, fundamental differences exist 
between the functional outcomes mediated by the two receptors in the induction of T cell 
effector functions, such as cytokine production and cell mediated cytotoxicity (43). Both these 
activities are the result of induction by the mature TCR only. In contrast pTCR signals result 
in allelic exclusion at the TCRb locus, and the initiation of TCRa locus rearrangement (44-
46). These differences raise the points whether pTCR and mature TCR have distinct signaling 
because of the difference in the cell population they operate or the functional differences are 
the reflection of their structural difference (i.e., the pTa chain in pTCR). 
 The pTa chain contains a longer cytoplasmic tail compared to the TCRa chain (~ 30aa 
in mouse pTa, ~110aa in human pTa vs. 6-8 aa in TCRa chain), indicating it might 
contribute to the unique role of pTa (47,48). Thymocytes from pTa-deficient mice show an 
impaired ability to transit from the DN to DP stage of T cell development (49). In addition, 
thymic cellularity was greatly reduced and the enforcement of allelic exclusion was impaired 
at the TCRb locus, emphasizing the important role played by pTa chain in early thymocyte 
development (49,50). Surprisingly, replacement of the pTa with a tail-less pTa chain restored 
T cell development almost to normal levels, indicating that the dispensability of the 
cytoplasmic tail for pTCR functioning (51). However, expression of the tail-less pTa chain in 
mice could not result in a complete rescue of cellularity in the thymus. 
 There exists a lot of incongruity regarding the ligand-dependent or ligand- 
independent signaling by the pTCR complex. Studies on truncated expression of pTCR show, 
pre-T cells could progress through the b-selection checkpoint by expressing a pTCR that 
lacked extracellular portions, suggesting that specific ligand recognition was not required 
(52,53). Other reports indicate the ligand independent signaling of pTCR could be due to its 
spontaneous localization and aggregation in the lipid rafts because of a palmitoylation signal 
in the pTa chain (54). 
As both pTCR and mature TCR share significant structural similarity and both 
transmit signals via the CD3 complex it was assumed that the signaling properties of both 
receptors might be similar. Studies on gene deficient or gene mutated mouse models and from 
manipulated T cell precursors in fetal thymic organ culture (FTOC) indicate that b-selection 
plays three important roles in early thymocyte development: (i) it induces proliferation; (ii) it 
promotes differentiation and survival; and (iii) it enforces allelic exclusion at the TCRb gene 
locus. 
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Proliferation, differentiation and survival 
 b-selection is initiated on a small subpopulation of post-mitotic CD44-CD25+, DN3 
thymocytes termed as ‘E-cells’ for expected size (55). Failure of productive TCRb gene 
rearrangement results in E-cells undergoing apoptosis. Those that succeed express a 
‘functional’ TCRb protein and the pTCR complex triggers proliferative expansion (estimated 
8-10 cell divisions) and maturation to the CD4+CD8+ DP stage (43,56). One of the earliest 
detectable effects of b-selection is entry into the cell cycle and increased cell size, for which 
b-selected cells were termed ‘L-cells’ for larger than expected (55). Unlike E cells, L cells are 
enriched for in-frame TCRb rearrangements and have up-regulated CD5 expression, 
suggesting that they have received an activation signal (55,57). L cells, by down-modulating 
CD25 transit to the most mature DN subset, CD44-CD25- cells, where the expression of 
Rag1, Rag2, and pTa are downregulated. By first upregulating CD8 to become immature 
CD8 single positive (CD8 ISP) and then CD4, CD44-CD25- DN4 cells develop to the DP 
stage. During transition from CD8 ISP to the DP stage, sterile transcripts are generated from 
the TCRa locus, indicating that the accessibility of TCRa locus for rearrangement (58,59).  
Allelic exclusion 
Besides facilitating the proliferative expansion of DN4 cells eligible to attempt TCRa 
rearrangements, b-selection also plays a critical role in regulating the activity of the site-
specific V(D)J recombination machinery. Once the successful rearragement at one of the 
TCRb gene locus is acheived the rearrangement at the remaining TCR b allele is prevented; a 
process otherwise known as allelic exclusion (60). This might be the result of induction of cell 
cycle during transition from the E to L stages. The correlation between cell cycle and 
prevention of rearrangement could be due to the degradation of Rag proteins once the cells 
enter cell cycle. Phosphorylation of Rag2 by the cdc2 mitotic kinase complex in vitro 
decreases Rag protein stability by 20 fold (61). Moreover, Rag2 protein level is decreased 
approximately 20 fold in cycling L and DN4 cells, but is re-expressed in post-mitotic DP 
cells. But in addition to the deficiency of Rag2 protein there could be other mechanisms 
involved in allelic exclusion at the second TCRb locus, as after re-expression of Rag proteins 
in the DP stage, the TCRb locus still remains inaccessible. Further, proliferation induced by 
b-selection can be attenuated by eliminating the activity of Rho GTPase; yet, allelic exclusion 
at the TCRb locus could not be reversed (62). The long-term control of gene-rearrangement is 
most likely controlled through locus accessibility, which, in turn is controlled by enhancer 
function. Indeed, both the b and a enhancers are required to initiate rearrangement at the b 
and a loci, respectively.  
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 Thus, pTCR mediated b-selection induces thymocyte proliferation, differentiation to 
the DP stage, and redirects the V(D)J recombination machinery from the TCRb locus to the 
TCRa locus. 
1.2.3 Proximal signaling molecules activated downstream of pTCR complex 
Even though the exact molecular nature of pTCR signaling is yet to be clarified significant 
information have been derived from the studies involving various gene targeted mice models. 
Although a number of molecules have been characterized to play a critical role in pTCR 
signaling, the effect of their impairment can vary substantially. 
Tyrosine kinases 
Studies from mice doubly deficient for Lck and Fyn show these two Src kinases play an 
important role in pTCR signaling as thymocytes from these mice are arrested at the CD44-
CD25+ DN3 stage (Fig. 1B) (63,64). Lck appears to be the more important of the two because 
(i) b-selection and allelic exclusion are severely compromised in Lck single deficient mice 
and in mice overexpressing a kinase dead Lck mutant (65,66), (ii) a constitutively active Lck 
transgene restores development of pTCR deficient thymocytes to the DP stage (67), and (iii) 
neither Fyn deficiency nor over-expression of a kinase inactive form of Fyn disrupts pTCR 
function (11,13). Surprisingly, constitutively active Fyn can substitute for Lck in pTCR 
expressing but not pTCR deficient thymocytes (63). In conformity with Lck’s importance in 
pTCR signaling, deletion of Csk, a kinase which phosphorylates and inactivates Lck, obviates 
the need for the pTCR by deregulating Lck activity (68). Conversely, CD45, a phosphatase 
which dephosphorylates and activates Lck, interferes with pTCR signaling (69). An important 
target for Lck activity is the z-associated protein of 70kD or ZAP-70, a member of the ZAP-
70/Syk tyrosine kinase family, whose recruitment to the TCR complex and activation by Lck 
is necessary for TCR signaling (70). However, in ZAP-70 deficient mice there is a complete 
block in the ab TCR-induced maturation of DP thymocytes to CD4+ or CD8+ single positive 
stage (Fig. 1B), but the pTCR driven maturation of DN thymocytes to the DP stage is 
relatively normal (71,72). This could most possibly be the outcome from compensation by the 
other ZAP-70/Syk kinase family member, Syk, as mice doubly deficient in ZAP-70 and Syk 
exhibit a complete block in development at the CD44-CD25+ DN3 stage (Fig. 1B), similar to 
the observation from overexpression of a dominant negative ZAP-70 mutant. 
Adaptor proteins 
The SH2 domain containing leukocyte phosphoprotein of 76 kD or SLP-76 is a downstream 
target of ZAP-70, which is rapidly phosphorylated following TCR ligation. SLP-76 as an 
adaptor molecule plays an essential role in both TCR signaling, as well as in the functioning 
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of the pTCR (73,74). SLP-76 deficient mice show a block in b-selection (Fig. 1B) (75,76). 
Adaptor molecules function by linking tyrosine kinase activation to downstream effector 
molecules. Indeed, phosphoSLP-76 links ZAP-70 kinase activity to GTP binding protein 
activation in two ways (i) by recruiting the guanine nucleotide exchange factor (GNEF) Vav, 
which can activate Rac-1, a Rho family GTPase and (ii) through association with Grb-2, 
another adaptor protein which recruits Sos, a GNEF capable of activating the GTPase Ras 
(77). The role of Ras in pTCR function remains unclear because a dominant negative Ras 
transgene has no effect on pTCR function, yet, a constitutively active Ras transgene can 
restore development of pTCR deficient DN thymic precursors to the DP stage, thus, 
compensating for pTCR function (78,79). Many other adaptor molecules have been identified 
as tyrosine kinase substrates in T cells and one of these, LAT or linker for activation of T 
cells, has been reported to be essential for both TCR and pTCR signaling (80). 
Ser/Thr kinases 
Activation of the Rho and Ras GTPases lead to the activation of the JNK/SAPK and 
MAPK/ERK serine/threonine (Ser/Thr) kinase cascades (81). Alterations of these pathways 
have been demonstrated to have differential effects on TCR mediated positive and negative 
selection at the DP stage. However, their role in early thymocyte development and pTCR 
function is still not clear (81,82). Mutations of kinases in the SAPK pathway have either no 
effect on the DN to DP transition or have yielded conflicting results. Moreover, unlike 
tyrosine kinases the role of Ser/Thr kinases in thymocyte development is relatively less clear. 
1.2.4 Involvement of transcription factors in controlling b-selection 
Recent studies have characterized a number of transcription factors, which either facilitate or 
inhibit the b-selection process. Overexpression or deletion of different transcription factors 
during early thymocyte developmental stages indicates how differential gene expression could 
affect normal T cell development. The involvement of transcription factors belonging to 
different groups points to the complex nature of signaling involved in the b-selection process 
(Fig.2).  
E-proteins and Id-proteins 
  
E-proteins belong to the basic helix-loop-helix (bHLH) transcription activators that bind to E-
box motifs in the regulatory sequences of a number of genes as homo-or heterodimers with 
other HLH proteins. In thymocytes bHLH-DNA binding complexes are mostly consist of 
heterodimers of E47 and HEB (83). T cell development in mice lacking HEB is blocked at the 
ISP stage, with 10 fold fewer thymocytes compared with wild type controls (84). Targeted 
deletions of E47 in wt type mice reduced the cellularity of the thymus, severely affecting 
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thymocyte development at a stage prior to ab-T cell lineage commitment, before the initiation 
of TCRb rearrangement (85). These studies indicate that HEB and E2A have unique roles in 
transcription control during early thymocyte development. 
 Id proteins act as antagonists of E2A and HEB DNA binding activity. Over-expression 
of Id3 in lymphoid precursor populations was shown to block T cell development in favor of 
NK cells (86). Recent studies have indicated that upon mimicking a pTCR signal, Id3 is 
upregulated through the ERK-MAPK signaling cascade. Thus upon formation of the pTCR 
E2A activity could be inhibited through the formation of E2A-Id3 heterodimers. 
SCL-LMO 
 
Stem cell leukemia (SCL) factor also belongs to the bHLH transcription factor family. E2A-
SCL heterodimers in conjunction with non-DNA binding zinc finger-like proteins, LMO1 or 
LMO2, can act as transcriptional activators or repressors. During thymocyte development, the 
expression of SCL, LMO1, and LMO2 decreases as immature thymocytes differentiate. 
Enforced expression of SCL and LMO1 at later DN thymocyte stages blocks thymocyte 
differentiation by inhibiting E2A-HEB function (87). The phenotype of the developmental 
block resembles to that of the HEB-/- mouse, with a block at the ISP stage (84,87). 
Notch signaling 
Notch is a transmembrane protein that is cleaved during biosynthesis by a furin-like activity 
to produce a noncovalently associated extracellular fragment and a cytoplasmic fragment.  
Mammals have four different notch proteins (Notch1-4). The interaction of notch with one of 
its ligands (Jagged 1 (JAG1), JAG2 or d-like 1 (DLK1) in mammals) induces a further 
cleavage of the molecule just inside the plasma membrane, which is mediated by presenilin/g-
secretase. The released intracellular fragment (Notch-IC) regulates gene expression by its 
effects on RBP-Jk and Deltex (88). 
 Notch signaling plays an important role during thymocyte development from DN 
thymocytes to SP cells. Notch 1 gene expression is high in early DN thymocytes, low in DP 
cells and intermediate in CD4+ and CD8+ SP cells whereas, Notch 3 expression levels are 
significantly higher in DN and DP thymocytes (89). The presence of multiple Notch receptors 
and their differential expression along the different developmental steps indicates different 
receptors play distinct roles during thymocyte differentiation. Notch signaling has been linked 
to pTCR signaling and also Notch 1 has recently been shown to be essential for correct VDJb 
rearrangement (276).  
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Wnt signaling 
 
Binding of Wnt proteins with their ligand at the cell surface transduce a signal to several 
intracellular proteins that include Dishevelled (Dsh), GSK-3b, Axin, Adenomatous Polyposis 
Coli (APC) and the transcriptional regulator, b-catenin. b-catenin is a key player in the Wnt 
signaling cascade and is responsible for activating the transcription factors T cell factor-1 
(TCF-1) and lymphocyte enhancer factor-1 (LEF-1) (90). An important role for b-catenin in 
the regulation of b-selection  has been  proposed as expression of  soluble mutant receptors in  
 
 
 
Figure 2. Schematic diagram of the transcription factors that are implicated in the control of b-selection. 
 
FTOC lead to a block in T cell development at the DN to DP transition (91). Moreover, 
disruption of the TCF-1 DNA binding domain results in a delay in the transition from the ISP 
to the DP stage of T cell development (92). This partial block appears to be compensated for 
by LEF-1 as TCF-1 mutant plus LEF-1-/- deficiency results in an arrest at the ISP stage. 
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 b-catenin is degraded in absence of Wnt signaling. However, stabilization of b-catenin 
expression results in the differentiation of thymocytes to the SP stage in the absence of b-
selection, i.e., in the absence of a pTCR signal (93). A similar phenotype is observed in 
Ikaros-deficient thymocytes, where it was noted that thymocytes differentiated to the DP stage 
in the absence of a pTCR (94). Therefore there may be a connection between Ikaros 
preventing Wnt-dependent differentiation in the absence of TCR signals. 
NFAT and NF-kB  
Pre TCR signaling induces activation of nuclear factor of activated T cell (NFAT) and nuclear 
factor kB (NF-kB) (95,96). While NF-kB does appear to be constitutively active in pTCR 
deficient thymocytes, NF-kB activity is upregulated either by expression of the pTCR in DN4 
thymocytes or by mimicking pTCR signals (by anti-CD3 treatment of Rag-/- mice). 
Additionally, NFAT activity is activated downstream of the pTCR, and this activity is 
indispensable for the transition of thymocytes through b-selection (96). NF-kB and NFAT 
activation both occur in response to increases in intracellular Ca2+ levels. 
 Transgenic mice encoding either IkB kinase b (IKKb) or IkBa, both regulators of the 
NF-kB signaling cascade, has established that activation of NF-kB results in a selective 
survival signal for thymocytes that have generated a functional TCR b chain (96). Moreover, 
IKKa overexpression in Rag-/- mice resulted in a slight increase in thymic cellularity but DN 
cells differentiated into DP thymocytes, indicating that activation of NF-kB could be involved 
in differentiation process. Results from these studies have provided evidence for the 
importance of NFAT and NF-kB transcription factors in b-selection and pTCR mediated 
signaling.  
c-Myb 
The Myb protooncogene encodes a nuclear, DNA-binding protein (c-Myb) that functions as 
both a transcription activator and repressor. During T cell development c-Myb expression is 
independent of any particular stage or population. Tissue specific deletion of c-Myb during T 
cell development shows, c-Myb activity is essential for DN3 to DN4 transition, survival of 
DP cells and differentiation of CD4+ thymocytes (97). 
1.2.5 Positive and negative selection 
 
At the DP stage, developing thymocytes undergo extensive selection processes to ensure that 
the mature T cells coming out of the thymus are functional and tolerant to self-antigens. These 
processes are termed positive and negative selection and are dependent on lymphostromal 
interactions within the thymus (98,99). Positive selection is a consequence of whether the 
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TCR on the developing thymocytes is able to recognize (self) peptide within the context of 
self-MHC (100). Those that can not recognize self-MHC-peptide complex die by neglect. In 
contrast, thymocytes with very high affinity for self-MHC-peptide are deleted by negative 
selection, an active apoptotic process to remove self-reactive T cells (101). Thymocytes with 
intermediate affinity are selected to develop into CD4+CD8- or CD4-CD8+ single-positive 
(SP) thymocytes, with concomitant downregulation of the CD8+ or CD4+ coreceptor 
molecules respectively. Development into CD4+T-helper cells requires interaction with MHC 
II-expressing thymic stromal cells, while development into CD8+ cytotoxic T-lymphocytes 
(CTLs) requires interaction with MHC I-expressing thymic stromal cells (102,103). 
Results from reaggregated thymic organ culture (RTOC) have established that MHC 
I+ and MHC II+ cortical thymic epithelial cells (cTEC) are both necessary and sufficient for 
positive selection of DP thymocytes and development of SP thymocytes. In addition, the 
concentration of peptide presented and the accessory molecules involved are also important in 
determining the strength of the signal that determines whether the thymocyte undergoes 
positive or negative selection (104,105). 
 Due to the TCR diversity of the developing thymocytes, a large array of self-peptides 
is required for efficient positive selection (99). The difference in antigen processing between 
TECs and hemopoietically derived APCs plays a significant role in the thymic selection 
process. Importantly, TECs, but not APCs, have been shown to express cathepsin L (106), 
which may potentially influence the peptides presented for positive selection compared to 
negative selection. DP thymocytes undergo many phenotypic changes before the generation 
of functional CD4+ and CD8+ SP thymocytes. Sustained interaction between the thymocytes 
and thymic stromal cells is essential for transition through these stages (107). Induction of 
positive selection correlates with the transient upregulation of the early activation marker 
CD69 (108), which discriminates MHC-dependent and –independent stages of thymocyte 
positive selection (109). Other phenotypic changes include downregulation of CD4/CD8 
coreceptor molecules and Rag1/Rag2, and upregulation of abTCR and CD5 (110,111).  
Self-nonself discrimination results in the elimination of autoreactive T cells during 
differentiation in the thymus. This process termed negative selection leads to establishement 
of central tolerance by an apoptotic mechanism that ensures the positively selected 
thymocytes do not have too strong an affinity for their specific peptides. The requirements for 
negative selection differ from those for positive selection in both, the cell types that mediate 
selection and the thymic niche where it occurs. Negative selection of thymocytes has been 
reported in various experimental systems to occur either at the cortico-medulary junction or 
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within the thymic medulla, induced mainly by bone marrow-derived thymic stromal cells 
(112-114).  
 
1.3 Protein Kinase B (PKB/Akt): forms and functions  
1.3.1 Origins of PKB 
Staal and co-workers are credited with initiating the PKB/Akt research in 1977 with their 
discovery of a transforming murine leukaemia virus from the AKR strain of mice with a high 
incidence of spontaneous lymphoma  (115). A retrovirus termed Akt8 was isolated from one 
of these lines derived from a spontaneous thymoma. The non-viral DNA component 
transduced from the mouse genome was subsequently identified, and two human homologues, 
PKBa and PKBb, cloned (116). The chromosomal location of the human PKB was mapped to 
chromosome 14q32 (117), proximal to the immunoglobulin-heavy-chain locus (118), a region 
frequently affected by translocations and inversions in human T-cell leukaemia/lymphoma, 
mixed lineage childhood leukaemia and clonal T cell proliferations in ataxia talengiectasia, 
supporting a role for this oncogene in development of a variety of tumors (119). Analysis of a 
number of human tumors revealed a 20-fold amplification of PKBa in a primary gastric 
adenocarcinoma. PKBb was mapped to chromosome region 19q13.1-q13.2 and shown to be 
amplified and overexpressed in several ovarian cancers and pancreatic cancer cell lines 
(120,121). Moreover, amplification of PKBb was especially frequent in undifferentiated 
tumors, suggesting that PKBb alterations may be associated with tumor aggressiveness. 
1.3.2 Cloning of Protein Kinase B  
In 1991, the cellular homologue of v-Akt was cloned independently by several groups and 
was characterized to be a 57 kD protein serine/threonine kinase (122-124). The kinase shows 
maximum similarity to protein kinase A (PKA) and protein kinase C (PKC), hence was 
named both protein kinase B (PKB) (122) or Related to A- and C-kinase (RAC-PK) (123). In 
mammals three genes encode three different forms of PKB (termed as PKBa/Akt1, b/Akt2 
and g/Akt3 (Fig. 3). PKBb and PKBg are approximately 82% identical with PKBa, although 
PKBg lacks 23 amino acids at the C-terminus compared with others.  
 Sequence analysis of PKB/Akt and v-Akt c-DNAs revealed that the viral gene is a 
fusion between a truncated tripartite viral group-specific antigen gag and PKBa/Akt1. This 
structure explains a mechanism for oncogenic activation of PKB. The viral gag protein is 
myristoylated at its N-terminus and normally targeted to the plasma membrane. PKB is 
normally a cytoplasmic protein (90%), whereas v-Akt is myristoylated and dispersed among 
various cellular compartments, with 40% being localized to the plasma membrane, 30% 
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nuclear and 30% cytosolic (124). This differential cellular localization probably has important 
consequences for regulation and function of PKB. 
1.3.3 PKB expression 
PKB is an ubiquitously expressed serine/threonine kinase with all tissues contain at least one 
form of PKB. PKBa and PKBb have highest expression in brain, thymus, heart and lung 
(122,123). Expression of the g isoform is more restricted with high expression in brain and 
testis and lower in heart, spleen, lung and skeletal muscle. Currently, the regulation of 
expression of PKB is not clear; however, it is upregulated in terminally differentiated cells.  
1.3.4 Targeted disruption of PKB 
Two of the three PKB/Akt genes have so far been disrupted in the mouse germ line. PKBb -
null mice are viable, but have defective insulin metabolism (125). Mice with disrupted PKBa 
gene are also viable. However, these mice show defects in the induction of apoptosis and their 
growth is retarded. Thymocytes from PKBa-/- mice show higher sensitivity to apoptosis 
induced by g-irradiation and dexamethasone treatment (126). The viability and relatively mild 
phenotypes of the individual knockout mice point to the compensatory effect of the three gene 
products for each other, although the phenotypes of these animals do indicate that the three 
gene products have unique functions. However, PKBa/PKBb double-knockout (DKO) mice 
exhibit severe growth deficiency and die shortly after birth. These mice display impaired skin 
development, severe skeletal muscle atrophy, impaired bone development and impeded 
adipogenesis (127).  
1.3.5 Domain structure of PKB 
  
All three PKB ‘isoforms’ consist of a conserved domain structure: a N-terminus pleckstrin 
homology (PH) domain, a central kinase domain and a C-terminus regulatory domain that 
contains a hydrophobic motif, which is a characteristic of AGC kinases (Fig. 3). The PH 
domain interacts with membrane lipid products such as phosphatidyl- 
ionositol(3,4,5)trisphosphate [PtdIns(3,4,5)P3] produced by phosphatidylionositol 3-kinase 
(PI3-kinase). Biochemical analysis revealed that the PH domain of PKB binds to both PtdIns 
(3,4,5)P3 and PtdIns(3,4)P2 with similar affinity (128,129). 
 The kinase domain of PKB, located in the central region of the molecule, shares a high 
similarity with other AGC kinases such as PKA, PKC, p70S6K, p90RSK (130). All three 
PKB isoforms have a C-terminal extension of around 40 amino acids, which harbors the F-X-
X-F/Y-S/T-Y/F hydrophobic motif (where X is any amino acid) that is characteristic of the 
 18 
AGC kinase family (130). For all AGC family kinases, phosphorylation of the Ser or Thr 
residue in this hydrophobic motif is necessary for full activation of the kinase. 
1.3.6 Regulation  
Phosphatidylionositol 3-kinase (PI-3K) mediates PKB activation 
PKB has been shown to be a downstream target of PI-3K, a pluripotent lipid kinase involved 
in many signaling pathways. PI-3K phosphorylates phosphoinositides (PtdIns) at the 3-
position of the inositol ring, generating PtdIns3P, PtdIns(3,4)P2 and PtdIns(3,4,5)P3. PKB as a 
PI-3K target was evident from two major observations: (i) inhibition of PI-3K activity by 
wortmanin completely blocked PKB activation after growth-factor stimulation, and (ii) 
growth-factor-receptor point mutations that prevented the activation of PI-3K also inhibited 
PKB. PKB was found to be rapidly and transiently phosphorylated by platelet-derived growth 
factor (PDGF), epidermal growth factor (EGF), basic fibroblast growth factor (bFGF) and  
 
            
  
Figure 3. Domain structure of the three PKB isoforms. Each isoform consists of an N-terminal PH domain 
containing region for binding inositol phospholipids, a kinase domain, and a C-terminal regulatory domain. 
Residues contained within ovals are serine and threonine sites inducibly phosphorylated in response to various 
cell stimuli. Other residues in PKBa/Akt1 known to be phosphorylated constitutively but not thought to regulate 
catalytic activity are also highlighted. Tyrosine residues Y315 and Y326 have recently been described as having 
a potential role in the regulation of PKBa/Akt1 activity. The equivalent phosphorylation sites in PKBb/Akt2 and 
PKBg/Akt3 have been obtained from sequence databases. 
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insulin. Subsequently PKB has been shown to be activated by a wide variety of stimuli 
including haemopoietic cytokines such as IL-2, IL-3, IL-4, IL-5, chemokines (IL-8, 
RANTES), heat shock, hyperosmolarity, hypoxia, integrins, the T cell antigen receptor and 
nerve growth factor (131-135). 
Mechanism of PKB activation 
PKB as a direct target of PI-3K indicates that the 3’-phosphorylated lipid products of PI-3K 
could be involved in its activation (Fig. 4). These lipids, such as PtdIns(3,4)P2 and 
PtdIns(3,4,5)P3 , specifically associate with the PH domain and thus recruit PKB to the plasma 
membrane. 
Activation of PI-3K leads to PKB phosphorylation at two residues, Thr308 within the 
kinase domain and Ser473 in the hydrophobic motif. Mutagenesis of each residue to alanine 
proved that both residues are essential for full activation (136). Furthermore, substitution with 
aspartic acid residues rendered PKB partially active and independent of agonists or inhibition 
by PI-3K antagonists such as wortmanin.  
  
 
 
 
Figure 4. Proposed model for PKB/Akt regulation. Receptor ligand interaction leads to PI-3K activation 
which in turn activates PDK1. PKB/Akt is then phosphorylated on Thr308 and Ser473 by PDK1, and by an as yet 
unidentified Ser473 kinase. Abbreviations: PDK1, phosphoinositide-dependent kinase 1; PH, pleckstrin 
homology; S473-K, kinase phosphorylating S473; T308-K, kinase phosphorylating T308. (TIBS. 2001;26:657-664) 
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PDK1 has been shown to be the kinase responsible for Thr308 phosphorylation in PKB. The 
primary structure of this kinase is similar to other AGC kinase family members, with a PH 
domain at its carboxy-terminal. PKB and PDK1 both need to be translocated to the plasma 
membrane for full activation (137,138). 
The role of PDK1 for Thr308 phosphorylation was confirmed by gene targeting in 
mouse embryonic stem (ES) cells. The deletion of PDK1 in ES cells resulted in inhibition of 
PKB, p70S6K and p90RSK activation, with complete inhibition of phosphorylation on the 
Thr residue in their activation loops. For PKB, co-localization with PDK1 to the plasma 
membrane is necessary for Thr308 phosphorylation, whereas, other AGC kinases are 
phosphorylated by PDK1 in the cytosol. 
Compared to the Thr308 phosphorylation the kinase involved in phosphorylation of 
Ser473 is not yet clear. There are few reports describing PKB itself as a Ser473 kinase under 
certain conditions (139,140). Recently Hill et al. (141) reported to isolate a protein kinase 
activity that specifically phosphorylates Ser473. 
Activated PKB/Akt mediates its intracellular effects (Fig.4), and then becomes 
inactivated by the action of phosphatases such as PP2A, which dephosphorylate pThr308 and 
pSer473 and return PKB/Akt to its inactive conformation in the cytosol. PTEN (phosphatase 
and tensin homologue on chromosome ten) is a multifunctional phosphatase and acts to limit 
PKB/Akt activation by dephosphorylating PtdIns(3,4,5)P3’ a lipid required for PKB/Akt 
activation. 
1.3.7 Physiological functions of PKB 
PKB ‘isoforms’ contribute to a variety of cellular responses, including cell growth, cell 
survival and metabolism. Up to now, more than 50 proteins have been identified as putative 
substrates for PKB. Peptide sequences that are preferentially phosphorylated by PKB were 
characterized by Alessi et al. (142) and Obata et al. (143). The minimal substrate consensus 
sequence for PKB is RXRXXS/T, where X is any amino acid and S/T is the phosphorylation 
site. Almost all reported PKB substrates have this minimal sequence. 
Metabolism 
GSK3 by phosphorylating inactivates glycogen synthase in response to insulin stimulation. 
Both isoforms of GSK3, GSK3a and GSK3b, have the phosphorylation site in the amino-
terminal region (Ser21 and Ser9, respectively). They are phosphorylated and inactivated by 
PKB in a PI-3K-dependent manner. GSK3 is involved in signaling pathways other than 
insulin signaling, such as the wnt signaling pathway (see above). 
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Table 1. List of protein kinase B (PKB)/Akt substrates  (TIBS. 2001;26:657-664) 
*The amino acid phosphorylated by PKB is in bold font. 
Protein PKB phosphorylation sites Species Effect of phosphorylation 
 
BAD 107RSRHSSY113   Human  Blocks BAD-induced    
                                                                                                         apoptosis 
C-raf 130RGRSRSA137   Human Inhibits C-raf activity 
B-raf 254RQRSTST260   Human Inhibits B-raf activity 
 423RERKSSS429 
BRCA-1 504KKRRPTS510   Human Interferes with nuclear   
                                                                                                         localization of BRCA-1?  
CREB 128LSRRPSY134   Human Increased association with  
CBP and p130 
eNOS  1174RIRTQSFSL1181   Human Activates eNOS and leads 
to NO production 
FKHRL1 248RRRAVSM254   Human Inhibits transcriptional  
activity of FKHRL1 
GSK-3a 16RARTSSF22    Human Inactivates GSK-3 activity 
GSK-3b 4RPRTSSF10    Human Inactivates GSK-3 activity 
I-kB kinasea 18RERLGTG24   Human Activates transcriptional  
activity of NF-kB 
IRS-1  297RSRTESI303    Murine Protects IRS-1from the  
action of PYPase 
mTOR  2443RTRTDSY2449   Murine Inhibits mTOR activity 
PDE-3B 268RPRRRSS274   Murine Inactivates PDE-3B 
PFK-2  460RMRRNSF467   Bovine Activates PFK-2 
  478RPRNTSV484    
Rac1  66RIRPLSY72    Human Inhibits Rac1-GTP binding 
hTERT 819RIRGKSY825   Human Enhances telomerase  
activity 
p21CIP1  139RKRRQTS146   Human Causes cytoplasmic  
localization of p21CIP1 
Nur77  345RGRLPSK351   Human Inhibits transcriptional  
activity of Nur77 
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The mammalian target of rapamycin (mTOR) is a regulator of mRNA translation in 
the signaling pathway controlled by nutrients such as amino acids. PKB phosphorylates 
mTOR on Ser2448 and activates this kinase (144). However, other report shows that this 
phosphorylation does not increase p70S6 kinase activity, which is a downstream target of 
mTOR (145). 
Regulation of apoptosis  
BAD (Bcl2/BclX antagonist) is a member of the Bcl2 family of proteins that binds Bcl2 and 
BclX and inhibits their anti-apoptotic potential (146). Phosphorylation on Ser136 by PKB 
prevents BAD to execute its proapoptotic function by interfering in its interaction with Bcl2 
and BclX. Caspase 9 acts as an initiator and effector of apoptosis (147,148). PKB can 
phosphorylate pro-caspase 9 on Ser196 in a Ras-dependent manner, which inhibits cytochrome 
C-induced cleavage of pro-caspase 9 essential for its enzymatic activity. Mutation of Ser196 to 
Ala reduces the apoptosis-inducing activity of pro-caspase 9 transfected into fibroblasts (148). 
 It has been reported that PKB can phosphorylate three kinases upstream of stress-
activated protein kinase (SAPK). Apoptosis signal regulated kinase 1 (ASK 1) is one of the 
MAP kinase kinase kinase (MKKK) that interacts with and is phosphorylated by PKB on 
Ser83, which results in the inhibition of SAPK pathway and subsequent apoptosis (149). PKB 
can phosphorylate another MKKK upstream of SAPK, the mixed lineage kinase 3 (MLK3). 
PKB phosphorylates MLK3 on Ser674 and this causes MLK3 inactivation and the promotion of 
cell survival (150). SEK1/MKKK4 is a direct upstream kinase for JNK, and p38 is also 
reported to be a PKB substrate. Similar to the two MKKKs mentioned above, SEK1 binds to 
and is phosphorylated on Ser78 by PKB, resulting in its inactivation and inhibition of 
ultraviolet (UV)-induced apoptosis (151). 
Transcription factors 
Transcription factors of the forkhead family (FH or FOXO factors) play a crucial role in cell 
cycle and apoptosis. To date, four isoforms of FH proteins (FKHR/FoxO1, FoxO2, 
FKHRL1/FoxO3 and AFX/FoxO4) have been shown to be directly phosphorylated by PKB 
(152,153). Phosphorylation of FH by PKB leads to it nuclear exclusion and thus decreased 
transcriptional activity resulting progression of cell cycle. 
 Members of the NF-kB/Rel family are key regulators of the immune response, and 
deregulation of its activity is implicated in the development of diseases such as autoimmune 
disease and cancer (154,155). In most cases, NF-kB activation is dependent on the 
phosphorylation and degradation of IkB, an inhibitor of NF-kB, by the IkB kinase (IKK) 
complex. PKB has been shown to regulate IKK activity in both direct and indirect manners. 
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Ozes et al. (155) reported that PKB interacts with and phosphorylates IKKa on Thr23 in a PI3-
kinase dependent manner. Another study has shown that PKB phosphorylates the Ser/Thr 
kinase Tpl-2 (or Cot) on Ser400, resulting in IKK complex activation (156). Activation of 
survival genes by NF-kB activation results in the inhibition of apoptosis. 
 Besides, PKB also phosphorylates a number of other transcription factors involved in 
various cellular functions. These include, cyclic AMP (cAMP)- response element binding 
protein (CREB) (157) and orphan nuclear receptor Nurr77 (158) in a PI3-kinase dependent 
manner. 
Cell cycle regulators  
  One of the p53 target genes, p21CIP1, is a cyclin/Cdk inhibitor which plays a crucial 
role in maintaining cell cycle progression, and its impaired function is one of the major 
abnormalities in many cancer cells (159). p21CIP1 is reported to be a direct substrate for PKB, 
and its phosphorylation results in the inhibition of its potential to arrest cell cycle. Zhou et al. 
(160) first reported that phosphorylation of p21 on Thr145 by PKB inhibits nuclear localization 
of p21CIP1, leading to activation of cyclin/cdk required for HER-2/neu-dependent tumor cell 
growth. Other groups however, have suggested different mechanisms for the regulation of 
p21CIP1 by phosphorylation (161). 
 p27KIP1, another major cyclin/cdk inhibitor, is also regulated by PKB dependent 
phosphorylation. Simultaneously, three groups demonstrated direct phosphorylation of p27KIP1 
by PKB in breast cancer cells (162-164). PKB phosphorylates p27KIP1 on Thr157, located in its 
nuclear localization signal (NLS), which excludes p27KIP1 from the nucleus and results in the 
activation of cyclin/cdk and cell cycle progression. 
 p53 is one of the most important regulators for cell cycle progression and apoptosis in 
response to genotoxic stresses (165). Murine double minute 2 (MDM2) is an oncogene 
product induced by p53 (166). This ubiquitin E3 ligase directly binds to p53 and targets it for 
ubiquitination. In 2001, two groups reported that PKB-dependent phosphorylation might 
contribute to nuclear localization of MDM2 (167,168). Two putative phosphorylation sites, 
Ser166 and Ser186, were determined by site-directed mutagenesis. However, the detailed 
mechanism of MDM2’s regulation by PKB needs further investigation. 
 Besides, PKB also regulates a number of other substrates. These molecules are 
involved in a multitude of cellular functions and include endothelial nitric oxidase synthase 
(eNOS) (169,170), the Ser/Thr kinase Raf (171,172) and p47 phox NADPH oxidase (173).  
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1.3.8 PKB/Akt in the immune system 
In T cells TCR ligation leads to the activation of PKB via induction of PI-3K. Expression of 
an activated PKB (gagPKB) allele in T cells resulted in decreased sensitivity to a variety of 
proapoptotic inducers, such as irradiation and exposure to Fas ligand (174). CD4+CD8+ DP 
thymocytes from these mice showed upregulation of the antiapoptotic protein, BclXL, and 
enhanced NF-kB activity, which probably both contribute to the reduction in apoptosis. As 
the mice aged, evidence of autoimmunity was observed, along with increased populations of 
B cells and T cells and increased immunoglobulin levels (especially IgA) (175,176). These 
effects most probably reflect the increased longevity of activated cells as a consequence of 
reduced clearance by Fas induced apoptosis that normally occurs at the conclusion of an 
immune response. Abnormal activation of PKB could therefore contribute to inflammatory 
diseases in addition to cancer progression. Together, these animal models have begun to 
unravel the physiological consequences of PKB activation. However, as PI3K induces many 
other signaling pathways, with similar regulation of other protein kinases, like SGKs, and 
there is a growing evidence of the overlapping functions among the downstream kinases, it is 
difficult to ascribe any particular function to PKB specifically.   
 
1.4 Nuclear Factor of Activated T cell (NFAT): forms and 
functions 
The NFAT family of transcription factors comprises of five proteins that have similarity to the 
Rel/NF-kB family (177). Four of the NFAT proteins (NFAT1-NFAT4), also known as 
NFATc1-c4; (Table 2) are sensitive to Ca2+ dependent regulation and NFATc1, c2, and c3 are 
lymphoid specific NFATs, whereas, NFATc4 is expressed outside the lymphoid system. 
 The distinguishing feature of NFAT is its regulation by Ca2+ and the Ca2+/calmodulin-
dependent serine/threonine phosphatase calcineurin. NFAT proteins are phosphorylated and 
reside in the cytoplasm in resting cells; upon stimulation, they are dephosphorylated by 
calcineurin, translocate to the nucleus, and become transcriptionally active, thus providing a 
direct link between intracellular Ca2+ signaling and gene expression. NFAT activity is further 
modulated by additional inputs from diverse signaling pathways, which affect NFAT kinases 
and nuclear partner proteins. 
 It is clear that NFAT activates transcription of a large number of genes during an 
effective immune response (178-181). Besides, NFAT participates in the early phase of 
chromatin remodeling at specific genetic loci and plays a crucial role in the T cell 
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differentiation program. Also, there is evidence that NFAT regulates cell differentiation 
programs in cell types other than immune cells (182), such as, fibre-type specification in 
differentiated skeletal muscle, cardiac valve development, and osteoclast differentiation. 
1.4.1 Functional domains in NFAT proteins 
Three functional domains are critical for the activation and function of NFAT proteins (Fig. 
5). These are, the rel similarity domain (RSD) or the DNA binding domain (DBD), 
responsible for DNA binding activity and interaction with AP-1 proteins; the NFAT 
homology region (NHR) or the regulatory domain, also known as calcineurin binding domain 
(CBD), regulates the intracellular localization; and the transcriptional activation domains 
(TADs). 
Rel-similarity domain (RSD) 
The most prominent feature of NFAT proteins is a highly conserved amino acid sequence (~ 
65%) of about 290 amino acids. This domain has been referred to as the Rel-similarity 
domain because of its distant relationship (~20% sequence identity) to the DNA-binding 
domain of the Rel/NF-kB family of transcription factors (183).  
 Consensus derived from the alignment of NFAT-binding sites of several promoters 
results in a core consensus sequence, 5’-GGAAA-3’ for DNA binding, for all NFAT family 
members. Therefore, a certain amount of redundancy or compensation by co-expressed NFAT 
proteins is likely. 
NFAT homology region (NHR) 
In all NFAT proteins, the RSD is preceded by an amino terminus sequence of about 400 
amino acids (Fig. 5). This sequence can be divided into an amino-terminal region of 100 
residues of little conservation and a serine/proline-rich region of about 300 residues of 
moderate similarity (~35% identity), termed the NFAT homology region. The main function 
of the NHR appears to be the control of intracellular localization of NFAT proteins (184-187). 
Deletion of NHR in NFATc2 or NFATc3 resulted in NFAT nuclear activity in absence of 
calcium mobilization (184,188). With regard to intracellular localization, the NHR seems to 
control at least four mechanistically different steps: nuclear import, nuclear localization, 
nuclear export and cytoplasmic localization. 
Alignment of the NFAT NHR sequences revealed eight motifs of conserved residues (Fig. 5) 
(186,189). One of these motifs encodes a nuclear localization signal (NLS), which is essential 
for NFAT nuclear translocation. Mutations in the highly basic NLS motif in NFATc2 or 
NFATc1 resulted in their reduced translocation to the nucleus (185,186). An additional NLS 
sequence is also present in the RSD. 
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Figure 5. Domain structure and phosphorylation of NFAT proteins. The N-terminal transactivation domain 
(TAD-N), regulatory domain, DNA binding-domain and C-terminal domain of NFAT proteins are indicated. 
Some forms of the proteins have altered N-termini or are truncated at their C-termini due to alternative splicing. 
The regulatory domain is enlarged to show conserved sequence motifs as colored boxes: two serine-rich regions 
(SRR-1 and SRR-2), three SPxx repeat motifs (SP-1, -2, and -3), a major calcineurin docking site (PxIxIT), a 
nuclear localization sequence (NLS), and a conserved YRE/D sequence that forms part of the gatekeeper region 
(YRE). Phosphorylated residues are shown as filled circles based on data from NFAT1 (190): conserved 
phosphoserines that become dephosphorylated upon activation are shown in red, non-conserved phosphoserines 
in grey, the conserved phosphoserine situated N-terminal to the NLS in black; and the inducible phosphorylation 
site in the N-terminal transactivation domain in green. (Oncogene. 2001;20:2476-2489) 
 
 
Conserved motifs in the NHR, in addition to the NLS, include a serine rich region (SRR, also 
called calcineurin-regulated-inhibitory (CRI) sequence), three copies of the serine-proline 
(SP) box of sequence SPxxSPxxSPxxxxx, a nuclear export sequence (NES) and other 
uncharacterized motifs (Fig. 5) (184,185,189). Interestingly, deletion of the SRR motif in 
NFATc3 or mutation of serines in the SRR motif in NFATc1 resulted in constitutively nuclear 
proteins, indicating that SRR motif masks the NLS sequence and thereby negatively regulates 
NFAT nuclear translocation (184,185). 
Transcriptional-activation domains (TADs) 
In NFATc2, two different TADs have been identified (188), one at the first 100 amino acids 
in the amino-terminus, and the other, within the last 200 amino acids in the carboxy terminus 
of NFATc2. Inducible phosphorylation of the TADs has been observed for NFATc2, and 
mutations of the modified serines eliminate transcriptional activity (190). Two TADs have 
also been found in the same regions of NFATc3. 
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1.4.2 Cellular inputs that affect NFAT   
Ca2+ and calcineurin 
In T cells NFAT is activated via increase in intracellular Ca2+ upon TCR ligation. Activation 
is initiated by dephosphorylation of the NFAT regulatory domain which is heavily 
phosphorylated in resting cells. Calcineurin dephosphorylates NFATs at this domain in SRR1, 
SPxx repeat, and SRR2 motifs, thus triggering NFAT nuclear accumulation and increasing the 
affinity of NFAT for its target sites in DNA (191). 
Efficient dephosphorylation requires a docking interaction between NFAT and 
calcineurin (192,193). The major docking site for calcineurin is located at the N-terminus of 
the NFAT regulatory domain, and has the consensus sequence PxIxIT (SPRIET in NFATc2). 
When Ca2+ entry is prevented or calcineurin activity is inhibited, NFAT is rephosphorylated 
by various NFAT kinases and rapidly leaves the nucleus, and NFAT dependent gene 
expression is terminated (194). 
NFAT kinases 
NFAT kinases are an important component of the regulatory mechanism responsible for 
NFAT activation. NFAT kinases located either in the cytoplasm or inside the nucleus 
phosphorylate the serine residues present in various motifs in the calcineurin binding 
regulatory domain of NFATs. GSK3 has been shown to be a NFAT kinase (195). Many 
studies have indicated various other serine kinases like ERK, JNK and casein kinase (CK) as 
possible NFAT kinases. However a clear picture of various NFAT kinases is still to emerge. 
The many serine residues that control NFATc2 nuclear localization are located in 
diverse sequence contexts that are unlikely to be recognized by a single kinase. Thus it could 
be possible that several constitutively active kinases co-operate to maintain the inactive, 
phosphorylated state of NFAT in resting cells, also in a similar way several inducible and/or 
constitutive kinases may act to rephosphorylate NFAT that has been dephosphorylated during 
cell activation. Sequence comparisons show that the SRR-1 region is extended in NFAT2-4, 
whereas the SP-2 and SP-3 motifs are truncated in NFAT3 (190); thus different NFAT 
proteins may be regulated by overlapping but distinct sets of constitutive and inducible 
kinases. 
Although several NFAT kinases have been identified, an integrated picture of NFAT 
phosphorylation has not yet emerged. CK1 and GSK3 are constitutive NFAT kinases that 
promote NFAT nuclear export (195,196). The MAP kinases p38 and JNK are inducible 
kinases. JNK1 phosphorylates NFATc1 and NFATc3, whereas p38 selectively targets 
NFATc2 and NFATc4 (197-199). 
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Figure 6. Schematic model of NFAT activation in T cells. TCR ligation induces intracellular increase in Ca2+ 
which then activates calcineurin. Activated calcineurin dephosphorylates NFAT and facilitates its nuclear 
localization. GSK3 phosphorylates NFAT and promotes NFAT nuclear exclusion. PKB upon activation via 
TCR/CD28 ligation inactivates GSK3 and thereby regulates NFAT activation. 
 
 
In T cells, T-cell receptor stimulation is coupled to Ca2+/calcineurin signaling and 
NFAT nuclear import, whereas stimulation through the costimulatory receptor CD28 
potentiates activation of the PI-3 kinase pathway and hence the kinase Akt/PKB (200). PKB 
phosphorylates GSK3 and renders it inactive. Thus the net effect is that CD28 costimulation, 
by activating PKB, inhibits GSK3 and therefore NFAT nuclear export (201). 
In T and B cells NFATs interact with AP-1, GATA proteins and many other 
transcription factors, co-activators and repressors to execute their target gene expression or 
repression. NFAT induced gene expression plays a crucial role in cytokine production, Th1 
and Th2 lineage decision and regulation of apoptosis and cell cycle (263, 264, 283, 284). 
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Table 2. NFAT family members and Phenotype of NFAT knock out mice (Mol Cells. 
2004;18:1-9) 
NFAT  Presence in Regulation Chromosomal  Phenotype of knockout 
Protein immune cells   location*  mice 
 (human/mice) 
NFAT1 Yes  Ca2+/  20q13.2-q13.3/ Enhanced B and T cell 
(NFATp,   calcineurin 2 95.5 cM  response.Th2 bias with 
NFATc2)        increased Th2 cytokines  
 
NFAT2 Yes  Ca2+/  18q23/   Embryonic lethal (cardiac 
(NFATc,   calcineurin 18 54.0 cM  valve defect), reduced B  
NFATc1) and T cell proliferative  
response, impaired Th2 
response with decreased 
                                                                                                          IL-4production.    
 
NFAT3 No  Ca2+/  14q11.2/  Viable and fertile with 
(NFATc4)   calcineurin 14 C1   defects in axon outgrowth. 
            
NFAT4 Yes  Ca2+/  16q22.2/  Mildly impaired developm-  
(NFATx,   calcineurin 8 51.0 cM  ent of CD4 and CD8 SP 
NFATc3)        thymocytes, (increased apo- 
                                                                                                          ptosis of DP thymocytes), 
                                                                                                          mild hyperactivation of  
                                                                                                          peripheral T cells. 
 
Double KO        Impaired effector T cell 
(NFAT1 +        function (reduced Th1 and 
NFAT2)        Th2 cytokines), but hyper- 
                                                                                                          reactive B cell function                         
        
Double KO        Lymphoproliferative disor-  
(NFAT1 +         der (hyper-reactive TCR, 
NFAT4)        defect in T cell apoptosis) 
          (Continued……..) 
 30 
allergic blepharitis and 
intestinal pneumonitis 
(increased Th2 response). 
 
Double KO        Embryonic lethal (E11) 
(NFATc3 +        with generalized defect in 
NFAT4)        vessel assembly, excessive 
and disorganized growth of 
vessels into the neural tube 
and somites.  
 
NFAT5 Yes  Osmotic stress 16q22.1/ Renal atrophy and lack of 
(TonEBP)   integrin (a6b4) 8 53.0 cM tonicity-responsive gene 
expression (aldose reduc-
tase, Na+/Cl2- coupled 
betaine/ GABA transporter, 
and the Na+/myo-ionositol 
cotransporter) 
 
1.5 Calcineurin: forms and functions 
1.5.1 Calcineurin properties 
Calcineurin, the Ca2+/calmodulin dependent serine/threonine phosphatase, is a heterodimer 
consisting of a 58 kD catalytic subunit, calcineurin A, and a 19 kD regulatory subunit, 
calcineurin B. Evidences suggest that all eukaryotic organisms possess one or more genes for 
each subunit. 
Calcineurin A 
In addition to calcineurin (PP2B), the serine/threonine protein phosphatase family members 
include protein phosphatase 1 (PP1), 2A (PP2A), and 2C (PP2C), phosphatases essential for a 
number of signal transduction pathways in eukaryotic cells. PP2A was originally described as 
having no requirement for divalent metal ion, calcineurin is regulated by Ca2+/calmodulin, and 
PP2C is Mg2+ dependent. Differences among these phosphatases are also found with regard to 
sensitivity to inhibition by macrolide inhibitors. PP2A and PP1 are inhibited by okadaic acid, 
whereas, calcineurin is specifically inhibited by the immunosuppressive drugs CsA and 
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FK506 in the presence of cyclophilin and FK506 binding protein (FKBP), respectively (202, 
203). 
 The active site of calcineurin is located on the A subunit which, in mammals, is 57-59 
kD depending on the isoform. All calcineurin A genes encode for a polypeptide consisting of 
a catalytic domain homologous to other serine/threonine protein phosphatases and three 
regulatory domains at the carboxy terminus that distinguish calcineurin from other family 
members (Fig. 7). These domains have been identified as the calcineurin B binding domain 
(204-206), the calmodulin-binding domain (207), and the “autoinhibitory” domain (208,209), 
which binds in the active site cleft in the absence of Ca2+/calmodulin (210) and inhibits the 
enzyme, acting in concert with the calmodulin binding domain to confer calmodulin 
regulation. 
 
 
 
 
Figure 7. Schematic representation of domain structure of calcineurin A. CaM, calmodulin: CNB, calcineurin B: 
AI, autoinhibitory. 
 
 
Calcineurin B 
The gene for mammalian calcineurin B encodes a protein of 170 amino acids containing four 
Ca2+-binding EF-hand motifs. The mature calcineurin B protein is myristoylated at the a-
amino group of glycine at position 2. At present, the contribution of myristoylation towards 
calcineurin function is unknown. 
1.5.2 Physiological roles of calcineurin 
Subcellular distribution 
Calcineurin is widely distributed in mammalian tissues, with the highest levels found in brain. 
Various studies show calcineurin is predominantly present in the cytoplasm and synaptosomal 
cytosol. There is overwhelming evidence for calcineurin in the nucleus along with other 
calmodulin-binding proteins such as casein kinase 2 and myosin light-chain kinase. In the 
context of signaling pathways that activate NFAT, Shibasaki et al. (187) have shown that 
calcineurin colocalizes to the nucleus along with dephosphorylated NFAT. Calcineurin has 
also been shown to be associated with the cytoskeleton (211).  
 
 
 32 
1.5.3 Calcineurin functions in the immune system 
In the immune system calcineurin plays a crucial role in thymocyte development, T 
lymphocyte activation, T cell anergy induction, cell cycle progression and T and B 
lymphocyte apoptosis. 
Calcineurin in thymocyte development 
 Expression of a constitutively active version of calcineurin in tg mice induced a block in 
early thymocyte development and an enhancing effect on selection of CD4 lineage T cells 
(212). Deficiency of calcineurin Ab the predominant calcineurin isoform expressed in 
lymphocytes shows impaired T cell development in terms of fewer CD3 positive cells and 
reduced number of CD4+ and CD8+ SP cells (213) i.e., positive selection was impaired. The 
duration and intensity of calcineurin activity in combination with the ERK pathway has been 
shown to regulate thymocyte lineage commitment (214). Also, by using FK506 as an effective 
inhibitor of calcineurin activity, Nakayama et al. showed that calcineurin activation plays a 
role in thymic positive selection but not in negative selection (215). However, deficiency of 
calcineurin Aa (CNAa) on a P14 TCR tg background showed no defect in thymic positive 
and negative selection, although mature T cell function was impaired (216). T lineage specific 
deletion of the calcineurin B1 subunit confirmed that calcineurin activity is essential in 
positive but not in negative selection (217).  
Calcineurin in T cell activationand anergy induction   
TCR ligation by appropriate antigen-MHC complexes induces intracellular Ca2+, which in 
turn activates calcineurin and NFAT. Nuclear NFAT plays a critical role in the coordinate 
gene expression of several genes, including various cytokines like IL-2, IL-3, IL-4, IL-5, GM-
CSF, IFN-g and TNF-a, and cell surface receptors such as CD40L, CTLA-4 and Fas L.  
Sustained calcium signaling induces a state of anergy or antigen unresponsiveness in T 
cells, mediated through calcineurin and NFAT. Activation of NFATc2 in the absence of AP-1 
appears to be required and sufficient for the induction of functional anergy in T cells (218). 
Ca2+-induced anergy seems to be a multistep process, implemented through proteolytic 
degradation of specific signaling proteins (219). 
Calcineurin in Cell cycle regulation 
Cyclin dependent kinase 4 (cdk4) is a crucial regulator of cell cycle progression at the G0/G1 
checkpoint. It has been shown that in Jurkat cells calcineurin specifically binds to cdk4 and 
inactivates the kinase by dephosphorylation, thus blocking cell cycle progression at the G0/G1 
checkpoint. Inhibition of calcineurin phosphatase activity by FK506 and CsA resulted in an 
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overall increase in cdk4 kinase activity, suggesting that the phosphatase activity of calcineurin 
was inhibitory to the kinase activity of cdk4 (220). 
Calcineurin and apoptosis 
Calcineurin has been implicated in the programmed cell death of T and B-lymphocytes 
(221,222). In T cell hybridomas apoptosis can be induced by ligation of the TCR/CD3 
complex. Both CsA and FK506 inhibit this process, implicating the involvement of 
calcineurin in the signaling pathway of apoptosis. Similarly, in B-cell lymphoma cell-lines 
apoptosis induced by cross-linking of surface immunoglobulin receptors was inhibited by 
these immunosuppressive drugs (223). 
 In lymphocytes, calcineurin and NFAT appear to participate in apoptosis, in part by 
mediating the induction of Fas and Fas L, which then interact and transduce the apoptotic 
signal after TCR ligation. Further, calcineurin forms a complex with Bcl2, which targets it to 
the cytoplasmic membrane (224). Although still catalytically active, calcineurin bound to Bcl2 
is unable to promote nuclear translocation of NFAT. Also, BAD, a proapoptotic member of 
the Bcl2 family, is a substrate of calcineurin. Dephosphorylation of BAD by calcineurin 
enhances BAD heterodimerization with Bcl-xL and apoptosis (225). 
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2. Objective of the study 
2.1 Concept 
Though PKB’s role in various cellular functions has been well studied in different cell 
systems, its precise role in the development and functioning of the immune system is 
relatively unknown. Numbers of studies though have implicated many kinases, mostly 
belonging to the tyrosine kinase family in early T cell development and function the role of 
Ser/Thr kinases in these events has just started to be unraveled. Keeping in view, the broad 
range of signaling pathways it regulates, it can be assumed that definitely it could play a vital 
role in T cell development and function. 
PI-3K has been implicated in regulating the nuclear factor of activated T cell (NFAT), 
via activation of PKB (226). Also protein kinase A (PKA) has been shown to regulate NFAT 
nuclear accumulation (227). PKA and PKB share similar consensus sequence for 
phosphorylation and both have sequence homology, being the members of AGC kinase 
family. Thus, probabilistically PKB, in fact could control NFAT signaling pathway in a way 
similar or different to that of PKA. 
Like PKB, calcineurin is also ubiquitous in expression and controls a range of cellular 
events. In principle by its sheer nature of being a Ser/Thr phosphatase it could be expected to 
play an opposite role to that of the ser/thr kinase PKB. In a physiological setup, a cross talk, 
leading to counteraction of each other’s function in modulating downstream events is most 
likely.  
In T cell development and function calcineurin exerts its positive or negative effects 
primarily through activation of NFATs. Various knockout models have proved its essentiality 
for thymocyte development and normal T cell function (213,216,217). Over-expression 
studies in calcineurin tg mice show dramatic effect in the form of severe block in thymocyte 
development (212). Thus in both the situations, (i) NFAT deficiency, in case of calcineurin 
knockout model and (ii) NFAT over-activity in case of calcineurin tg model, it is well 
established that calcineurin/NFAT signaling pathway is vital for normal T cell development 
and function. 
2.2 Hypotheses 
 
1. PKB can regulate NFAT signaling in T cells 
GSK-3 is a well-characterized substrate of PKB and has been shown to act as an NFAT 
kinase (195). Phosphorylated GSK-3 is functionally inactive. Thus in the Ca2+/calmodulin-
calcineurin-NFAT signaling pathway, PKB’s role is well evident via regulation of GSK-3. 
 36 
Theoretically, by inactivating GSK-3, it should enhance NFAT signaling, by prolonging 
nuclear duration of NFAT. Over expressed PKB (PKB tg mice), should in fact lead to 
stronger NFAT signaling upon T cell activation. 
 
2.  PKB can itself act as an effective NFAT kinase 
PKB is a Ser/Thr kinase and NFAT activation depends on the balance between 
phosphorylation and dephosphorylation of its many serine residues. One possibility is that, 
PKB itself could act on NFAT and phosphorylate the serine residues and thereby keep it in an 
inactive state, irrespective of its effect on GSK-3. In this situation, how the T-cell functions 
are modulated is of enormous interest. Thus in principle PKB itself can act as an NFAT 
kinase. 
 
3.  Possible crosstalk between PKB and calcineurin signaling at the level of NFAT 
Assuming PKB, as a NFAT kinase, it is of great interest to study how it will affect T- cell 
development in a setup where there is (i) an insufficiency of NFAT (NFAT k.o. model) and 
(ii) sufficiency of NFAT (calcineurin tg model). In calcineurin tg mice model, NFAT is 
constitutively nuclear and active, and in this model thymocyte development is severely 
blocked at a very early stage. Over expression of PKB in this model, in principle, should 
restore normal thymic development by acting on the overactive NFAT signaling, which is the 
main effector molecule in calcineurin induced block. We hypothesize PKB and calcineurin 
crosstalk with each other at the level of NFAT, to influence early thymocyte development. 
2.3 Experimental system 
   
To study the precise role PKB plays in T cell development and function, we have used a tg 
mouse model (myrPKB) where PKB is overexpressed and is constitutively active. This is to 
simulate an in vivo model for lymphomagenesis and how PKB modulates events that lead to 
development and progression of lymphomas and thymomas. 
 To delineate PKB’s regulation of NFAT activation, in T cell development and 
function, we have used a NFAT sufficiency model; i.e., calcineurin tg mouse model where, 
independent of Ca2+ signaling, NFAT is constitutively nuclear. Crossing calcineurin single tg 
mice with PKB tg mice we have the mice where both, Ser/Thr kinase PKB and Ser/Thr 
phosphatase calcineurin are overexpressed. This is an interesting model to study and prove 
our hypothesis concerning crosstalk between PKB and calcineurin, in modulating NFAT 
signaling during early thymocyte development. 
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3. Materials and Methods 
 
3.1 Materials 
3.1.1  Mice 
 C57BL/6 
PKB2 tg 
PKB5 tg 
OT1 tg  (228) 
∆Cam tg (Prof. E. Serfling, Institute of Pathology, Univ. of Würzburg) 
Rag1 -/- (Prof. M. Klein, Institute of Virology and Immunology, Univ. of 
Würzburg) 
PKB2/OT1 double tg 
∆Cam/PKB2 double tg 
∆Cam/PKB5 double tg 
∆Cam/OT1 double tg 
All mice used in this study were either one day or 6 to 8 weeks old unless mentioned 
otherwise. Mice were bred in the animal facility at the Institute of Virology and Immunology 
under pathogen free conditions. Institutional guidelines were followed in handling mice 
throughout the course of the study.  
3.1.2  Chemicals and reagents 
for proliferation assay : 
Reagents      Source 
CFSE (5-(and-6)-Carboxyfluoresceine  
diacetate succinimidyl ester)    Molecular Probe 
CsA (Cyclosporin A)     Sigma 
PD98059      Calbiochem 
PP1       Calbiochem 
LY294002      Calbiochem 
SB202190      Calbiochem 
UO       Calbiochem 
Staurosporin      Sigma 
Forskolin      Sigma 
PMA       Calbiochem 
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Ionomycine      Calbiochem 
for cell cycle analysis: 
Propidium Iodide     Sigma 
7-Amino actinomycin D (7-AAD)   Sigma 
Colcemid      Sigma  
Miscellaneous: 
Dimethyl Sulfoxoide (DMSO)   Sigma 
HEPES      Sigma 
Ethylene glycol tetraacetic acid (EGTA)  Sigma 
Ethylene diamine tetraacetic acid (EDTA)  Sigma 
Potassium chloride      Sigma 
Sodium citrate     Sigma 
Saponin      Sigma 
Glycine      Roth 
Tris       Roth 
Boric acid      Roth 
Magnesium chloride     Roth 
Sodium chloride     Roth 
Sodium azide      Sigma 
Bovine serum albumin (BSA)   Sigma 
Agarose      Applichem  
Polyacrylamide     Applichem 
Sodiumdodecyl sulfate (SDS)   Roth 
Ammonium persulfate (APS)   Sigma 
TEMED      Sigma 
Ethydium bromide     Roth 
Bromophenol blue     Roth 
Xylene cyanol      Roth 
Acetone      Roth 
Methanol      Roth 
Ethanol      Roth 
Chloroform      Roth 
Isopropanol      Roth 
Formaldehyde      Roth 
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Formamide      Sigma 
Cell strainers      Hartenstein 
Trypan blue      Sigma 
Proteinase K      SIGMA-Aldrich 
Complete Protease inhibitor    Roche 
Gene Ruler™ 100bp Ladder MBI Fermentas 
Cycloheximide Sigma-Aldrich 
ECL chemiluminescence kit Pierce 
CBA ELISA kit     BD Pharmingen 
Goat anti-rat IgG Fc Magnetic beads  Quiagen 
Protein G sepharose     Amersham/Biosciences 
Glutathione sepharose    Amersham/Biosciences 
Glutathione      Sigma 
Filters for FCS     S&Smicroscience 
Scintillation fluid (Betaplate Scint)   Wallac 
Trizol GIBCO/ Invitrogen 
NP-40 Sigma 
Bradford’s Reagent     BioRad 
Nitrocellulose membrane Amersham/ Bioscience 
Whatman filter paper Hartenstein 
Whatman membrane for NTOC Herolab 
96 well cell culture plates Cellstar 
96 well ELISA plates Nunc 
6 & 24 well cell culture plates Cellstar 
12 well cell culture plates TPP, Switzerland 
6 mm Petri dish Cellstar 
T-25, T-75 & T-250 tissue culture flasks Nunc 
Cuvettes Hartenstein 
FACS tubes Greiner 
 
3.1.3  Antibodies 
for proliferation assay : 
aCD3e (145.2C11)     BD Pharmingen 
aCD28 (37.51)     BD Pharmingen 
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for isolation of DN thymocytes, CD4+ and CD8+ T cells  
Hybridoma culture supernatants: 
Rat-anti-mouse CD4  (GK1.5) 
Rat-anti-mouse CD8   (YTS 169.4 & TiB 105) 
Rat-anti-mouse CD19  (1D3) 
Rat-anti-mouse NK1.1  (4D11) 
Rat-anti-mouse MHC II  (2G9) 
for ELISA: 
IL-2 ELISA      BD Pharmingen 
Capture antibody:  (Anti-mouse IL-2 mAb)    
Detection antibody:  (Biotinylated anti-mouse IL-2 mAb)  
Avidin-horseradish peroxidase conjugate 
Recombinant mouse IL-2 
 
CBA (Cytometric bead array) 
Mouse Th1/Th2 cytokine CBA Kit   BD Biosciences 
Mouse IL-2, IL-4, IL-5, IFN-g, TNF-a capture beads 
Mouse Th1/Th2 PE detection reagent 
Mouse Th1/Th2 cytokine standards 
Cytometer setup beads 
PE positive control detector 
FITC positive control detector 
Wash buffer 
Assay diluent 
 
for FACS staining: 
All antibodies were purchased from BD Pharmingen unless otherwise 
mentioned. 
Antibody   Clone 
anti-CD4 PE    (GK1.5)      
anti-CD4 FITC   (GK1.5)  
anti-CD4 bio    (GK1.5) 
anti-CD8 PE    (53-6.7) 
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anti-CD8 FITC  (53-6.7) 
anti-CD8 bio  (self made) 
anti-CD3 FITC  (145.2C11) 
anti-CD25 PE   (PC61) 
anti-CD25 FITC  (PC61) 
anti-CD25 bio   (PC61) 
anti-TCRb FITC  (H57-597) 
anti-TCRb bio  (H57-597) 
anti-CD44 FITC  (IM7) 
anti-CD2 bio   (RPA-2.10) 
anti-CD5 bio   (53-7.3) 
anti-CD24(HSA) bio  (M1/69) 
anti-CD69 bio   (H1.2F3) 
anti-CD62L bio  (Mel 14)    
anti-NK1.1 PE  (PK136) 
anti-LFA bio   (HI111) 
anti-CD49 bio   (9F10) 
anti-CD18 bio   (6.7) 
anti-Va2 bio   (B20.1) 
anti-Vb5 bio   (MR9-4) 
anti-Vb8 bio   (F23.1) 
anti-Vb11bio   (RR3-15) 
anti-Fc receptor  (24G2) 
anti-Rat IgG2ak  (R35-95)  
anti-Mouse Bcl2 FITC Bcl2 Antibody Sampler Kit 
 
for western blot analysis: 
 
Rabbit anti-mouse pPKB (ser-473)   NEB   
Rabbit anti-mouse PKB    NEB 
Rabbit anti-mouse pERK    NEB 
Rabbit anti-mouse ERK    NEB 
Rabbit anti-mouse pP38    NEB 
Rabbit anti-mouse pJNK    NEB 
Rabbit anti-mouse pGSK3    NEB 
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Rabbit anti-mouse Lamin A    NEB 
Mouse anti-mouse NFATc1    Alexis 
Rabbit anti-mouse NFATc2 Gift from Dr. A. Rao 
(CBR, Harvard Medical 
School, Boston)  
Rabbit anti-mouse NF-kB p65   Santa Cruz 
Rabbit anti-mouse NF-kB p50   Santa Cruz 
Rabbit anti-mouse Rel B    Santa Cruz  
Rabbit anti-mouse Rag1    Santa Cruz 
Goat anti-mouse Actin    Santa Cruz 
Rabbit anti-mouse IkBa    Santa Cruz  
Rabbit anti-mouse pIkBa    Santa Cruz 
Goat anti-rabbit HRP Jackson   Laboratories 
Goat anti-mouse HRP Jackson Laboratories 
Rabbit anti-goat HRP Jackson Laboratories 
Rabbit anti-human CRM1 Gift from Dr. G. Grosveld 
(St. Jude Children’s 
Research Hospital, 
Memphis, TN) 
for confocal microscopy: 
 
Mouse anti-mouse CD4 Alexa 647 conjugate Caltag 
Mouse anti-mouse CD8a Alexa 488 conjugate Caltag 
anti-Fc receptor (24G2) purified from hybridoma 
supernatant 
Rabbit anti-mouse NFATc1 & NFATc2 Prof. E. Serfling (Inst. of 
Pathology, Univ. of 
Würzburg) 
Rabbit anti-mouse NFATc3    Santa Cruz 
Rabbit anti-mouse pPKB (ser-473)   NEB 
Donkey anti-Rabbit Cy3    Molecular Probe 
DAPI       Molecular Probe 
 
for apoptosis analysis: 
Annexin V FITC     BD Pharmingen 
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3.1.4  PCR and RT-PCR Primers 
PCR:   
PKB transgene: 
F: 5’ –AGATTTCCTGTCCCCTCTCAGG-3’ 
R: 5’ –TGTTGGACCCAGCTTTGCAG-3’ 
 
Calcineurin (∆Cam) transgene: 
F: 5’ –CCGAGCCCAAGGCGATTGATCC-3’  
R: 5’ –CCCGGTTTCTGATGACTTCCTTCC-3’   
 
RT-PCR: 
Calcineurin 
F: 5’ –AAGGAGGGAAGGCTGGAAGA-3’ 
R: 5’ –CCTGACTGTGTTGTGAGTGAA-3’ 
 
Rag1 
   F: 5’ –TGCAGACATTCTAGCACTCTGG-3’ 
R: 5’ –ACATCTGCCTTCACGTCGAT-3’ 
 
b-Actin 
F: 5’ –CCAGGTCATCACTATTGGCAAGGA-3’ 
R: 5’ –GAGCAGTAATCTCCTTCTGCATCC-3’ 
PCR reagents: 
dNTPs      Roth 
MgCl2      Amersham 
10x Buffer     Amersham 
Taq Polymerase    Amersham 
RT-PCR reagents: 
Primer p(DT)15    Roche 
SuperscriptTM II RNase H  
Reverse Transcriptase   Invitrogen 
5X RT-PCR Buffer    Invitrogen 
0.1 M DTT     Invitrogen 
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3.1.5  Hybridomas:  
All hybridomas (rat-anti-mouse) were cultured in c-RPMI 1640 medium 
supplemented with 5% FCS 
anti-CD4      GK1.5 
anti-CD8     YTS 169.4 & TiB 105 
anti-CD19     1D3 
anti-NK1.1     4D11 
anti-MHC II     2G9    
        
3.1.6  Mediums and buffers 
 
for cell culture, proliferation assay and FACS staining: 
BSS (Balanced Salt Solution): 
1.07 g BES (N,Nbis[2-hydroxy-ethyl]-2-aminoethanesulfonic acid) 
1.6 g NaCl 
0.027 g Na2HPO4 
in 100 ml ddH20 pH 6.96 
+ 0.1% BSA (Bovine Serum Albumin) 
PBS (Phosphate buffered saline): 
8 g  NaCl 
 0.2 g   KCl 
1.44 g  Na2HPO4 
0.24 g  KH2PO4 
Dissolve in 800 ml dH2O, adjust pH to 7.4 with HCl 
Volume adjust to 1 L, autoclave and store at RT 
FACS-Buffer: 
PBS + 0.1% BSA + 0.01% Azide 
RPMI+ 1640 Medium:    Invitrogen, Karlsruhe 
+L-Glutamin (0.07%)   GIBCO 
+Na-Pyruvat (1 mM)     GIBCO 
+b-Mercaptoethanol (0.05 mM)  GIBCO  
+MEM (non essential amino acids) (1%) GIBCO 
+ Penicillin (100 U/ml),    Grunthal 
+ Streptomycin (100 U/ml) FatolGmbH  
+ FCS (Foetal calf serum) (1-10%)  GIBCO    
(heat inactivated at 56°C for 45 min) 
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Gey’s Solution: 
Solution A:    Solution B:   Solution C: 
35 g NH4Cl   0.42 g MgCl2 ,6 H2O  2.25 g NaHCO3 
1.85 g KCl   0.14 g MgSO4 ,7 H2O  add 100 ml H2O 
1.5 g Na2HPO4 ,2 H2O 0.34 g CaCl2  
0.12 g KH2PO4  add 100 ml H2O 
 5 g Glucose 
adjust to 1 L with dH2O 
Final solution (100ml):  
A+ B+ C+ ddH2O = 20 ml+ 5 ml+ 5 ml+ 70 ml 
for genomic DNA isolation and agarose gel electrophoresis: 
Tail Lysis Buffer: 
50 mM Tris pH 8.0 
100 mM EDTA  
100 mM NaCl 
1% SDS 
TBE Buffer (1x): 
10.8 g Tris 
    5.5 g Boric acid 
    0.37 g EDTA 
add   1 L H2O  
DNA Loading Buffer: 
0.25% Bromophenol blue 
0.25% Xylene Cyanol FF 
30% Glycerol in water 
store at 4°C 
1% Agarose Gel: (150 ml) 
1.5 g agarose  
150 ml 1x TBE buffer 
boil  
add 4 ml Ethidium bromide (10 mg/ml) 
for cell cycle analysis: 
Citrate buffer:   
0.1% Sodium Citrate 
0.1% Triton X-100 
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for apoptosis assay 
AnnexinV Buffer: (10x) 
 
0,1 M HEPES pH 7.4 
  1,4 M NaCl 
  25 mM CaCl2   
for IL-2 ELISA 
Coating buffer (0.1 M Sodium Carbonate, pH 9.5) 
8.40 g NaHCO3 
3.56 g Na2CO3 
Volume adjusted to 1L with dH2O 
Assay diluent 
PBS with 10% Foetal Bovine Serum, pH 7.0 
Wash buffer 
PBS with 0.05% Tween-20 
Substrate solution 
Tetramethylbenzidine (TMB)  
Hydrogen peroxide (H2O2) 
Stop solution 
2 N H2SO4 
for intracellular staining 
Saponin buffer: 
PBA (1x PBS, 5% BSA, 10 mM HEPES, pH 7.4 and 
0.02% NaN3 ) 
0.5% Saponin 
for cell counting 
Trypan Blue Solution: 
0.4% (w/v) Trypan Blue in PBS 
Dilute 1:10 in PBS for live cell counting 
for cell extract  preparation 
Whole Cell Extract (WCE) Buffer: 
20 mM HEPES (pH 7.4)   
2 mM EGTA (pH 7.9)   
50 mM b-Glycerophosphate  
50 mM Sodium fluoride   
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1% Triton X-100  
10% Glycerol 
0.04% Sodium azide   
adjust volume with ddH2O to 50.0 ml 
* Protease inhibitors to be added at appropriate concentration immediately            
before preparation of extract 
  1 mM DTT (Dithiothreitol) 
  1 mM Orthovanadate 
  2 mM Leupeptin 
  0.4 mM PMSF (Phenyl Methyl Sulfonyl Fluoride) 
 
Nuclear and Cytoplasmic Extract (NE & CE) Buffer: 
Buffer A (CE buffer):   Buffer C (NE buffer): 
10 mM KCl    420 mM NaCl 
10 mM HEPES pH 7.9  20 mM HEPES pH 7.9 
0.1 mM EGTA pH 7.9  1 mM EGTA pH 7.9 
0.1 mM EDTA pH 7.9  1 mM EDTA pH 7.9 
*Protease inhibitors to be added immediately before preparation of 
extract 
20 ml 50x Protease inhibitor/ml buffer 
1 mM DTT 
1 mM Orthovanadate 
SDS-PAGE  
Composition of SDS-Polyacrylamide gels 
  Resolving Gel: 
      Component volumes (ml) per 12 ml gel mix 
     8%   12% 
H2O     5.52 ml  3.96 ml 
30% acrylamide mix   3.24 ml  4.8 ml 
1.5 M Tris (pH 8.8)   3.0 ml   3.0 ml 
10% SDS    0.12 ml  0.12 ml 
10% ammonium persulfate  0.12 ml  0.12 ml 
TEMED    6 ml   4.8 ml  
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Stacking Gel: 
    Component volumes (ml) per 3 ml gel mix 
H2O     2.1 ml 
30% acrylamide mix   0.5 ml 
1.0 M Tris (pH 6.8)   0.38 ml  
10% SDS    0.03 ml 
10% ammonium persulfate  0.03 ml 
TEMED    3 ml  
 
Protein Loading Buffer (1X SDS Gel Loading Buffer): 
50 mM Tris.Cl (pH 6.8) 
100 mM Dithiothreitol 
2% SDS 
0.1% Bromophenol Blue 
10% Glycerol 
store at -20°C 
Gel Running Buffer: (10X) 
144.13 g Glycine 
30.3 g Tris  
100 ml 10% SDS 
volume adjusted to 1L with dH2O 
store at RT 
Protein Transfer Buffer: (10X) 
145 g Glycine 
29 g Tris 
volume adjusted to 1L with dH2O 
store at RT 
dilute 10X transfer buffer: methanol: dH2O in 1:2:7 ratio before use 
Ponceau S Solution: 
2 g Ponceau S 
30 g Trichloroacetic acid 
30 g Sulfosalicylic acid 
dH2O to 100 ml 
store at RT 
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Dilute 1:10 in dH2O for working solution 
Blocking Solution: 
5% (w/v) nonfat dried milk in PBS/0.1% Tween 
RNA analysis: 
DEPC H2O 
0.1% DEPC in dH2O 
stirr until DEPC is completely mixed in H2O 
Autoclave and store at RT 
MOPS Buffer: (10X) 
0.4 M MOPS 
0.1 M NaOAc 
0.01 M EDTA 
pH 7, autoclave and store in dark at RT 
Formaldehyde Buffer: 
15% Formaldehyde 
50% Formamide 
10% 10X MOPS buffer 
RNA Loading Buffer: 
0.5% Xylene cyanol 
0.5% Bromophenol blue 
10 mM EDTA 
50% Glycerol 
30% Formamide 
Fomaldehyde-Agarose gel electrophoresis: 
for 150 ml of 1.2% gel 
1.8 g Agarose 
15 ml 10X MOPS buffer 
98 ml dH2O 
------------------------------- 
boil  
add 27 ml formaldehyde in the fume hood 
3.1.7  Radioactive material  
3[H]-Thymidin  ICN Biomedicals 
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3.1.8 Instruments and accessories 
Agarose gel reader   Mitsubishi 
Microscope    Leica 
Multichannel pipette   Micronic 
Heat block    Hartenstein 
pH meter    Hanna Instruments 
Harvester “MACH 3”   Tomtec 
b-Counter “Micro Beta Trilux” Wallac 
Thermo-Cycler “Biometra”  Biotron 
Cytospin Centrifuge   Shandon 
Centrifuge “Megafuge 1,0R”  
and “Biofuge 13” Heraeus Instruments  
   FACScan    Beckton Dickinson 
   FACSCalibur    Beckton Dickinson 
   FACSSorter vantage SE  Beckton Dickinson 
ELISA-Reader “n-max”                    Molecular Devices  
   Ultraspec 2000, UV/Visible 
Spectrophotometer   Pharmacia Biotech 
CO2 incubator    Heraeus Instruments 
    Leica Confocal Microscope  Leica TCS SP II  
   Dynal Magnet    Dynal A.S. 
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3.2  Methods 
3.2.1   Generation of transgenic mice 
Myr PKB tg mice were generated in Dr. U. Bommhardt’s lab in the Institute of Virology and 
Immunology, University of Würzburg. The calcineurin tg (∆Cam) mice were generated and 
kindly provided by Prof. E. Serfling, Institute of Pathology, University of Würzburg, 
Germany. 
Construction of human PKB cDNA harboring the hemagglutinin (HA) epitope tag and 
the Lck myristoylation/palmitoylation signal (MGCWCSSNPEDD) for membrane targeting 
has been described previously (137). Myr-HA-PKB cDNA (myr PKB) was inserted into the 
EcoRI site of the human CD2 minigene cassette (229). The linearized hCD2-myr-HA-PKB 
fragment was microinjected into fertilized eggs from (CBA/J x C57BL/10) F1 animals. 
Transgenic founder mice were identified by DNA slot blots using a [32P-] DNA probe specific 
for the human CD2 cassette. Stable PKB transgenic lines were established by crossing 
transgenic mice to C57BL/6 mice. Transgenic mice were identified by PCR of genomic tail 
DNA. Mice used throughout the study were offspring from two founder lines (PKB2 and 
PKB5), which were crossed to C57BL/6 mice for at least three generations. 
The truncated murine calcineurin mutant was generously provided by Dr. R.L.Kincaid 
and described previously (230). The 1.2 kb fragment was cloned into the BamH1 sites of the 
expression cassette harbouring the murine proximal Lck promoter, a 3' human growth 
hormone fragment and the human CD2 LCR.  Spe I cut fragments were injected into oocytes 
from NMRI mice. Founder mice were crossed with C57/BL6 mice and offsprings were 
backcrossed to C57/BL6 mice for further analysis. Genomic integration of the ∆Cam 
transgene was determined by PCR of genomic tail DNA with primers specific for the Lck 
promoter and the transgene F: 5'-CCG AGC CCA AGG CGA TTG ATC C-3' and R:  5'-CCC GGT TTC 
TGA TGA CTT CCT TCC-3'.  
Mice heterozygous for ∆Cam were crossed with PKB tg mice or OT1 TCR tg (228) 
mice (both on C57/BL6 background) to generate ∆Cam/PKB and ∆Cam/OT1 double 
transgenic mice. In all experiments, F1 littermate mice negative for both ∆Cam and PKB, 
positive for ∆Cam only and positive for PKB only were used as wild type control and control 
for ∆Cam and PKB tg, respectively. Mice used were 1 day or 6 to 8 weeks old unless 
mentioned otherwise. Experiments with ∆Cam mice crossed to the C57/BL6 background were 
also performed and showed identical results.  
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3.2.2  Genotyping of mice 
Isolation of genomic tail DNA 
Genomic DNA from PKB tg, ∆Cam tg and ∆Cam/PKB double tg mice was isolated from 
mouse tail fragments which were incubated o.n. in 500 ml tail lysis buffer (TLB) 
supplemented with 10 ml of Proteinase K (20 mg/ml) per sample at 56°C in a shaking 
waterbath. Samples were boiled for 5 min at 80°C and centrifuged at 10,000 rpm for 10 min. 
DNA was precipitated by addition of 500 ml isopropanol per sample. Isolated DNA was 
solubilized in dH2O (56°C for 1hr) and was used in PCR for genotyping. 
PCR:  
PKB tg PCR  
Composition of reaction mix for one sample:     
Fwd primer (10 mmol) 1.0 ml 
Rev primer (10 mmol) 1.0 ml    
dNTP (10 mM)  0.4 ml    
MgCl2 (25 mM)  2.0 ml    
Buffer (10X)   2.0 ml    
dH2O    12.5 ml   
Taq polymerase (5U/ml) 0.1 ml    
Genomic DNA  1.0 ml     
   ______________  
20.0 ml 
PCR  condition: 
94°C  5 min     
94°C  1 min     
55.5°C  1 min  31 cycles   
72°C  1 min     
72°C  5 min     
4°C  pause     
The size of the PCR product for detection of the myr PKB tg is 360 bp. 
 
∆Cam tg PCR  
Composition of reaction mix for one sample:     
Fwd primer (10 mmol) 1.0 ml  
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Rev primer (10 mmol) 1.0 ml     
dNTP (10 mM)  0.5 ml     
MgCl2 (25 mM)  0.8 ml     
Buffer (10X)   2.5 ml     
dH2O    12.7 ml    
Taq polymerase (5U/ml) 0.5 ml     
Genomic DNA  1.0 ml      
   ______________     
    20.0 ml 
PCR  condition: 
95°C  1 min 
95°C  30 sec  
60°C  40 sec  40 cycles 
72°C  1 min     
72°C  7 min 
4°C  pause 
The expected size of the PCR product for the ∆Cam tg is 1.2 kb. 
PCR products for the respective transgenes were resolved in 1% agarose gels in 1X TBE 
electrophoresis buffer. 
 
3.2.3 Preparation of single cell suspension of thymocytes and LN cells 
Mice were killed by asphyxiation with CO2 and required organs were collected sterile in 
BSS/BSA on ice. Thymus and lymph nodes (LN) were mashed and passed through a nylon 
filter to obtain single cell suspensions. Cell suspensions were centrifuged at 1300 rpm for 5 
min at 4°C and resuspended in BSS/BSA. Live cells were counted by trypan blue exclusion 
with a haemocytometer.  
 
3.2.4  Isolation of DN thymocytes, CD4+ T cells, CD8+ T cells and FACS 
sorting 
Negative selection of DN thymocytes, CD4+ and CD8+ T cells 
For isolation of CD4-CD8- DN cells, total thymocytes were incubated with rat-anti-mouse 
CD4, rat-anti-mouse CD8, rat-anti-mouse NK1.1, rat-anti-mouse CD19 and rat-anti-mouse 
MHC II hybridoma supernatants for 25 min on ice with intermittent shaking. Cells were 
washed twice with PBS/0.1% BSA and were incubated with goat-anti-rat IgG coupled 
 55 
magnetic beads (Biomag/Quiagen) (2 ml of 10X concentrated beads per 1 X 106 cells) for 25 
min at 4°C with intermittent shaking. The tubes were filled with 5ml BSS/0.1% BSA and 
were placed on a magnet for 3 min for separation of labelled cells. Supernatant was collected, 
centrifuged at 1300 rpm for 5 min at 4°C and isolated cells were resuspended in cRPMI 1640 
medium supplemented with 10% FCS.  
CD4+ and CD8+ T cells from LNs were isolated as described above for DN 
thymocyte isolation and cells were suspended in 5% FCS cRPMI 1640 medium. Purity of 
isolated cells was controlled by flow cytometry for each experiment and routinely was 90 to 
95%. 
 
FACS sorting 
Total thymocytes were stained for CD4, CD8, CD25 and CD44 surface molecules. Gating on 
DN thymocytes, CD4-CD8-CD25+CD44- DN3 and CD4-CD8-CD25-CD44- DN4 cells were 
electronically sorted on a FACSVantage (Beckton Dickinson). 
 
3.2.5  Flow cytometry  
For three-colour analysis, 8 x 105 thymocytes were immunostained with CD4 and CD8 and 
either CD5, CD24, CD25, CD44, CD2 or TCRb, CD69, LFA1, CD18 and CD49d mAbs 
labelled with fluoresceine isothiocyanate (FITC), R-phycoerythrin (PE) or biotin in PBS 
containing 0.1% BSA and 0.1% sodium azide. Biotin-coupled Abs were revealed with 
streptavidin-cychrome. For further analysis of DN3 cells, thymocytes were gated on CD4-
CD8- CD25+ cells. For analysis of CD4+ peripheral T cells isolated CD4+ T cells or total LN 
cells were surface stained for expression of CD4, CD62L (Mel14), CD25 and CD69.  
 
3.2.6  Proliferation assay 
2 x 105 purified CD4+ or CD8+ T cells were cultured in triplicate in complete RPMI 1640 
medium supplemented with 5% FCS in 96 well plates coated with antiCD3e mAb alone or in 
combination with antiCD28 mAb. PD98059, PP1, LY294002, SB202190, staurosporin and 
cyclosporinA (CsA) were added at the beginning of the culture, unless otherwise mentioned, 
at the concentrations indicated. After 48 hrs cells were pulsed with 1mCi 3[H]-thymidine per 
well for 12 hrs. Cells were harvested in a Tomtec cell harvester and 3[H]-thymidine 
incorporation was determined by a Perkin Elmer scintillation counter. 
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3.2.7  CFSE labeling 
For analysis of cell division purified CD4+ or CD8+ T cells (1 x 107 cells/ml) were washed 
twice in PBS and labeled with CFSE at a final concentration of 2 mM in PBS for 5 min at RT. 
Cells were washed twice in cRPMI medium supplemented with 10% FCS and thereafter 
cultured in cRPMI 1640 mediun with 5% FCS at a density of 2 x 106 cells/ml in 96 well 
plates. Cells were activated with plate bound anti-CD3e mAb alone or in combination with 
anti-CD28 mAb for 2 or 3 days and were analysed by FACS. For short term activation, CFSE 
labelled cells were stimulated with plate bound anti-CD3e mAb for 12 or 18 hrs, harvested 
and recultured in fresh medium without further stimulus, until 24 or 48 hrs. 
 
3.2.8  ELISA 
2 x 105 purified CD4+ T cells were stimulated in triplicate in 96 well plates with plate bound 
anti-CD3e mAb alone or in combination with antiCD28 mAb for 2 or 3 days and culture 
supernatants were collected for analysis of Th1 and Th2 cytokine production by ELISA and 
Cytokine Bead Array (CBA). 
For interleukin 2 (IL-2) ELISA, 96 well plates were coated with 100 ml anti-mouse IL-
2 mAb (capture Ab) in coating buffer o.n. at 4°C. Plates were washed thrice with 200 ml wash 
buffer per well and were blocked with 200 ml/well assay diluent for 1 hr at RT. 100 ml of  
undiluted or diluted culture supernatant from PKBtg or wt CD4+ T cells, IL-2 standard and 
control samples were added to respective wells and incubated for 2 hrs at 37°C. Plates were 
washed five times with the washing buffer. Plates were then incubated with 100 ml of 
detection solution (biotinylated anti-mouse IL-2 plus avidin-horse radish-peroxidase reagent) 
for 1 hr at RT. Plates were washed five times and incubated with 100 ml of substrate solution 
for 30 min at RT in the dark. Reaction was stopped by adding 50 ml of stop solution to each 
well and absorbance at 450 nm was measured in an ELISA reader.  
IL-4, IL-5, IFN-g and TNF-a were measured by mouse Th1/Th2 cytokine bead array 
according to the manufacturer’s instructions. Briefly, mouse Th1/Th2 cytokine standards were 
reconstituted and serially diluted using the assay diluent. 10 ml of each cytokine capture bead 
suspension per sample were mixed and 50 ml of mixed beads were aliquoted to separate assay 
tubes. Cytokine standard dilutions and test samples (50 ml/ test) were added to appropriate 
sample tubes and 50 ml/test PE detection reagent was added to it. Samples were incubated for 
2 hrs at RT in the dark. Samples were washed with 1 ml wash buffer and resuspended in 300 
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ml wash buffer and were analyzed immediately by a FACSCalibur using CellQuest and BD 
CBA software.  
 
3.2.9  Cell cycle analysis: propidium iodide (PI) staining 
For analysis of various cell cycle stages 2 x 105 purified DN thymocytes were stained with 
propidium iodide at a final concentration of 50 mg/ml in citrate buffer for 30 min at RT. 
Nuclei were analyzed on a FACSCalibur using Cell Quest software and a doublet 
discrimination program. 
 
3.2.10 Apoptosis analysis: annexin V staining 
For apoptosis analysis of CD4-CD8-CD25+ DN3 thymocytes, total thymocytes were first 
stained for CD4, CD8 and CD25 surface molecules. Cells were then stained with AnnexinV 
for 15 min at RT in AnnexinV binding buffer. AnnexinV positive apoptotic and AnnexinV 
negative DN3 cells were determined by gating on CD4-CD8-CD25+ cells using FACSCalibur 
and Cell Quest software.   
 
3.2.11 Intracellular staining 
For intracellular staining, 7 x 106 total thymocytes were first stained for cell surface CD4, 
CD8 and CD25 molecules. Cells were then fixed with 1% paraformaldehyde (10 min at RT) 
and permeabilized in PBA (1x PBS, 5% BSA, 10 mM HEPES, pH 7.4 and 0.02% NaN3) 
containing 0.5% saponin (10 min at RT). Permeabilized cells were incubated with FITC-
labelled mAbs against CD3e, TCRb and Bcl2 diluted in PBA containing 0.5% saponin for 30 
min at 4°C. Cells were washed twice in 1 ml of PBA/0.5% saponin, once with 
PBS/0.1%BSA/0.01% azide and analyzed by FACS. 
 
3.2.12  NTOC (neonatal thymic organ culture) 
Thymi from wt and ∆Cam tg neonates (day 0-1) were collected aseptically and placed on 
nucleopore membranes and cultured in 2 ml complete RPMI 1640 medium containing 10% 
FCS in the absence or presence of 100 ng cyclosporin A (CsA) for 4 days. Subsequently 
single cell suspensions were made, immunostained for CD4 and CD8 surface molecules, and 
thymocyte subpopulations were determined by flow cytometry. Intracellular staining for 
TCRb expression was analyzed gating on the CD4-CD8- population. 
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3.2.13  Preparation of whole cell  protein extract (WCE) 
1x107 unstimulated DN thymocytes or 3 x 106 stimulated or unstimulated CD4+ T cells from 
the indicated mice were harvested, washed once in PBS and were incubated in 50 ml WCE+ 
(WCE + protease inhibitors) buffer for 30 min at 4°C. Samples were centrifuged at 14,000 
rpm for 15 min at 4°C and cell lysate was collected. For IkB analysis, cells were pretreated 
with cycloheximide (50 mg/ml) for 15 min before stimulation of cells with soluble antiCD3e 
mAb (1 mg/ml) in combination with antiCD28 mAb (5 mg/ml) for the indicated time periods. 
For longterm stimulation, cells were activated with plate-bound antiCD3e mAb (5 mg/ml).  
Protein concentration was estimated with Bradford’s reagent and lysates were stored at -20°C 
for further analysis.  
 
3.2.14  Preparation of nuclear and cytoplasmic protein extract (NE & CE) 
2 x 107 purified CD4+ T cells from wt and PKB2 tg mice were stimulated with anti-CD3e Ab 
alone or in combination with anti-CD28 Ab in presence or absence of CsA for the time points 
indicated in 5% FCS/cRPMI 1640 medium. Kinase inhibitors PD98059 (100 mM), LY294002 
(20 mM), SB202190 (40 mM), and staurosporine (10 nM) were added 1 hr before stimulation 
of cells.  Cells were harvested, washed once in PBS and were incubated for 3 min on ice with 
200 ml of buffer A+ (buffer A + protease inhibitors), supplemented with 0.5% NP-40. Samples 
were centrifuged at 14,000 rpm for 3 min at 4°C and supernatants were collected as 
cytoplasmic extract (CE). Samples were washed thrice with bufferA+ and suspended in 75 ml 
buffer C+ (buffer C + protease inhibitors), vortexed and incubated for 2 hrs at 4°C with 
shaking. Samples were centrifuged at 14,000 rpm for 15 min and supernatants were collected 
as nuclear extract (NE). CE and NE protein concentrations were determined with Bradford’s 
reagent and extracts were stored at -20°C for further analysis. 
 
3.2.15 Isolation of RNA, cDNA synthesis and reverse transcriptase polymerase 
chain reaction (RT-PCR) 
Total cellular RNA from purified DN thymocytes was prepared with Trizol reagent. 1 x 107 
unstimulated DN cells were homogenized with 1 ml Trizol reagent, incubated for 5 min at RT 
and chloroform at 0.2 ml/ml Trizol reagent was added to the samples. Samples were further 
incubated for 3 min at RT with vigorous shaking and were centrifuged at 14,000 rpm for 15 
min at 4°C. The aqueous phase was collected, and 500 ml isopropanol/ml trizol reagent was 
added and further incubated for 10 min at RT. Samples were centrifuged at 14,000 rpm for 10 
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min at 4°C and the RNA pellets were washed once with 75% ethanol. Pellets were briefly air 
dried and dissolved in DEPC water. RNA concentration was determined with a 
spectrophotometer.    
cDNA was synthesized with SuperScript reverse transcriptase from 1 mg of RNA as 
described by the manufacturer's protocol. Each sample was normalized by PCR for b-actin 
expression. Serially diluted cDNA was analyzed for expression of calcineurin (detecting bp 
301-909 of the N-terminus of calcineurin), RAG1 and b-actin using the following primers, 
calcineurin: F: 5'-AAG GAG GGA AGG CTG GAA GA-3' and R: 5'-GGC ATC CAT ACA GGC ATC AT-
3'; RAG1: F: 5'-TGC AGA CAT TCT AGC ACT CTG-3' and R: 5'-ACA TCT GCC TTC ACG TCG AT-3', 
and b-actin: F: 5'-CCA GGT CAT CAC TAT TGG CAA GGA-3' and R: 5'-GAG CAG TAA TCT CCT TCT 
GCA TCC-3'. 
 
RT-PCR: 
Composition of the reaction mix for individual RT-PCRs was identical to that 
of PKB PCR 
Calcineurin 
94°C  5 min 
94°C  45 sec 
54°C  45 sec  31 cycles 
72°C  45 sec   
72°C  10 min 
4°C  pause 
RAG1 
94°C  5 min 
94°C  45 sec 
55°C  45 sec  30 cycles 
72°C  45 sec    
72°C  10 min 
4°C  pause 
b-actin 
94°C  2 min 
94°C  1 min 
58°C  1 min  24 cycles 
72°C  1 min    
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72°C  5 min 
4°C  pause 
 
3.2.16 Western blot analysis 
For immunoblot analysis, 30 mg protein from whole cell lysates and 10 mg protein from NE & 
CE were denatured in 1X protein loading buffer and were fractionated on 8% SDS-PAGE. 
Proteins were transferred to nitrocellulose membranes o.n. at 4°C. WCE from DN thymocytes 
was analyzed for expression of pPKB (Ser 473), PKB, Rag1, and b-actin and WCE from 
CD4+ T cells was analysed for expression of cyclins B1 and D3, and IkBa.  NE & CE were 
analysed for expression for PKB, phospho-PKB (Ser473), phospho-GSK3a/b (Ser21/9), 
phospho-FKHR (Ser256), phospho-JNK, and phospho-p38, NFATc1, NFATp, NF-kBp65, 
NF-kBp50 and RelB. Primary Abs were detected by goat-anti-rabbit, goat-anti-mouse or 
rabbit-anti-goat Abs coupled with horse radish-peroxidase and enhanced chemiluminescence 
(ECL). Blots were reprobed with anti-actin Ab to control protein loading in the case of CE. 
Controls for NE and CE, which are designated as n.s. in the figures are nonspecific proteins 
used as protein loading controls.  
 
3.2.17 Immunoprecipitation (IP) 
For immunoprecipitation experiments, 1 x 107 CD4+ T cells from myr PKB tg or wt mice 
were lysed in buffer A, and cytoplasmic protein extracts were incubated with anti-PKB, anti-
phospho-PKB (pPKB) (Ser473), anti-Lamin A, or anti-NFATc1 Ab overnight at 4°C with 
shaking. After addition of 25 ml of 50% protein G-Sepharose for 1 hr at 4°C, extracts were 
centrifuged at 10,000 rpm for 1 min, and immunoprecipitates were washed four times with 
buffer A+. After the final wash, pellets were boiled in loading buffer, and supernatants were 
resolved on 8% SDS-PAGE. Coprecipitation was analyzed for association of NFATc1 with 
PKB or pPKB.  
 
3.2.18 Confocal microscopy 
Single cell suspensions of thymocytes (1 x 107 cells) were fixed in 500 ml 0.5% formaldehyde 
for 10 min at RT. Fixed cells were cyto-spinned onto poly-lysine coated glass slides. Slides 
were incubated for 15 sec in chilled acetone (-20°C) and cells were permeabilized by 
incubating in chilled methanol (-20°C) for 3 min. Subsequently, cells were washed thrice in 
PBS and were incubated with 50 ml goat-anti-mouse Fc block for 15 min in a humid chamber. 
 61 
Afterwards 40 ml of primary Ab solution for cell surface CD4 (Alexa-647) and CD8 (Alexa-
488) and intracellular NFATc1 or NFATc3 in appropriate dilutions in PBS containing 1% 
BSA was added to the cells for 45 min. Cells were washed thrice in PBS and then incubated 
for 45 min with donkey-anti-rabbit Alexa-555 conjugated Abs in the dark. Cells were washed 
thrice in PBS and twice in dH2O and then counter stained with DAPI for 5 min at RT for 
nuclear staining. Stained thymocyte preparations were analysed for NFAT expression in CD4-
CD8- thymocytes using a Leica TCS SPII confocal microscope. 
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4. Results 
Part I. Effect of PKB on T cell function  
 
4.1 Generation of transgenic mice expressing myr PKB in lymphocytes 
To investigate the role of PKB in T cell development, we established transgenic mouse lines 
expressing a human myr PKBa cDNA (137) under the control of the human CD2 promoter 
and locus control region (Fig. 8A) (229). Of six transgenic founder lines, three lines (PKB 2, 
5 and PKB 6) were crossed to the C57BL/6 background. Analysis of all three lines showed 
comparable results, with PKB 5 and PKB 2 being used throughout this study. Myr PKB 
expression in thymocytes and peripheral CD4+ and CD8+ T cells was determined by Western 
blots using anti-PKB and anti-phospho-PKB (Ser473) Abs (Fig. 8B & C). The kinase activity 
of myr PKB was verified for splenic CD4+ T cells in kinase assays as shown previously 
(231). All mice used in this study were heterozygous for myr PKB (PKB+/-). 
 
 
 
Figure 8. Generation of myr PKB transgenic mice. (A) Schematic representation of the myr PKB transgenic 
construct. (B and C) Expression of myr PKB in thymocytes and peripheral T cells. B, Thymocytes from wildtype 
(wt) and myr PKB transgenic lines (tg) were analyzed by Western blot using anti-PKB and anti-phospho-PKB 
(Ser473) Abs. Results are shown for three different transgenic lines, PKB 2, 6, and 5. Upper bands correspond to 
transgenic myr PKB, lower bands to endogenous (end) PKB. Anti-actin Ab was used to control equal protein 
loading. C, Western blot analysis for phospho-PKB (Ser473) expression in peripheral CD4+ and CD8+ T cells 
from wild-type and myr PKB transgenic mice (232). 
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4.2 Active PKB lowers the activation threshold of CD4+ and CD8+ T cells 
and confers resistance to CsA in proliferation  
To examine the effects of constitutively active PKB (myr PKB) on activation and 
proliferation of peripheral T cells, CD4+ and CD8+ T cells from wt and myr PKB tg mice 
were activated with either high (10 mg/ml) or limiting (1 mg/ml) concentrations of anti-
TCR/CD3 mAb alone or in the presence of CD28 costimulation. As shown in Fig. 9, strong 
TCR/CD3 stimuli led to comparable proliferation, whereas weak TCR/CD3 signals induced 
significant proliferation only in myr PKB CD4+ (Fig. 9A) and CD8+ (Fig. 9B) T cells. CD28 
costimulation had only small enhancing effect in tg T cells, whereas in wt T cells, 
proliferation was increased 10- to 20-fold. In addition, in wt cells the response to TCR 
engagement alone or to CD28 costimulation in combination with weak TCR engagement was 
totally blocked in the presence of CsA, whereas myr PKB T cells showed significant 
proliferation under these conditions. Thus, myr PKB signaling lowers the threshold for 
activation by providing costimulatory signals similar to those induced by CD28 and confers 
partial resistance to CsA treatment with regard to proliferation. 
 
4.3 Active PKB replaces CD28 costimulatory signals in cell cycle 
progression   
Next we analyzed the effect of myr PKB on cell cycle by labeling T cells with CFSE, which 
allows tracing the number of cell divisions undergone at any particular time point. As shown 
in Fig. 10A, 2 days after anti-CD3 activation, 30% of wt and myr PKB CD4+ T cells had 
divided once; however, 3-fold more (26%) myr PKB CD4+ cells had progressed through a 
second cell division compared with wt cells (9%). After activation with anti-CD3 plus anti-
CD28 mAbs, cell cycle in wt cells resembled that of myr PKB CD4+ T cells stimulated with 
anti-CD3 mAb only. In contrast, costimulation had only small enhancing effects on cell cycle 
progression in myr PKB CD4+ T cells. Comparable results were observed for day 3 cultures, 
in which the majority of myr PKB CD4+ T cells activated with either anti-CD3 mAb alone or 
in combination with anti-CD28 mAb had undergone four to six cell cycles, corresponding to 
the same pattern from CD28-costimulated wt cells. Wild type cells stimulated with anti-CD3 
mAb only showed a less synchronous cell division profile, with 20% of cells each having 
divided one to three times and with only 14% of cells having completed five or six cell 
divisions compared with 54% of myr PKB CD4+ T cells. As evident from Fig. 10B, myr PKB 
shows the same enhancing effects on cell cycle progression in CD8+ T cells; the  observed  
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Figure 9. Active PKB lowers the threshold for T cell activation and confers significant CsA resistance in 
proliferation. Purified CD4+ (A) and CD8+ (B) T cells from wt and tg mice were cultured in medium only or 
stimulated with plate-bound anti-CD3 mAb (CD3) at a concentration of 10 or 1 mg/ml or with anti-CD3 (1 
mg/ml) plus anti-CD28 (CD28; 5 mg/ml) mAbs in the presence or the absence of CsA (100 ng/ml). [3H]thymidine 
incorporation was measured 48 hrs after initiation of cultures. Data show averages from triplicate cultures of two 
wt and tg mice each and are representative for three experiments (233).  
 
advantage in the progression of the cell cycle in the case of CD8+ T cells is even more 
prominent than that in CD4+ T cells. These data attribute an augmentative role to PKB in cell 
cycle progression of CD4+ and CD8+ T cells by providing CD28-like costimulatory signals.  
To further dissect the role of PKB in cell cycle progression, CD4+ T cells from tg and 
wt mice were activated with anti-CD3 mAb for 12 or 18 hrs and were re-cultured without 
further stimulus until 24 or 48 hrs. As shown in Fig.10C, a 12hrs stimulation pulse was 
sufficient for 16% of myr PKB CD4+ T cells to enter into the cell cycle and divide once 
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within 24 hrs; on day 2, 54% of tg cells had undergone one to three cell divisions. In stark 
contrast, stimulation of wt CD4+ T cells for 12 hrs induced only 5% of cells to divide once 
within 24 hrs, and 3-fold fewer cells had divided twice or three times on day 2 compared with 
tg cells. When the activating stimulus was extended to 18 hrs, 19% of wt cells showed one 
round of cell division on day 2, similar to what was observed for tg cells on day 1. Together, 
these data clearly show that myr PKB strongly enhances cell cycle entry and progression and 
also sustains cell division.  
 
To define molecular mechanisms underlying the positive effect of myr PKB on the 
cell cycle, we analyzed the expression of cyclins D3 and B1, proteins regulating cell cycle 
entry and G2 phase transition, respectively. As shown in Fig. 10D, myr PKB accelerated and 
enhanced the induction of cyclin D3 and also increased cyclin B1 expression in activated T 
cells, thus providing a link between active PKB and the observed enhanced cell division. We 
also studied inactivation of the forkhead transcription factor FKHR, which, like other 
forkhead family members, is located in the nucleus in resting cells and is critically involved in 
cell cycle regulation. In various cell lines phosphorylation of these factors by PKB leads to 
their nuclear exclusion and thereby facilitates cell cycle entry and progression into M phase 
(234). In nuclear and cytoplasmic extracts of unstimulated wt cells (Fig. 10E, upper left 
panels), phosphorylated forms of FKHR could hardly be detected, whereas after TCR/CD3 
engagement, phospho-FKHR was strongly present in both fractions. Interestingly, 
cytoplasmic phosphorylated FKHR was already prominent in unstimulated myr PKB CD4+ T 
cells, and only low levels of nuclear FKHR appeared in stimulated cells (Fig. 10E, upper right 
panels), suggesting that most FKHR proteins had been phosphorylated and shuttled out of the 
nucleus. This correlates with tg PKB also being located in the nucleus (Fig. 10E, lower 
panels). Thus, increased or constitutive inactivation and nuclear export of FKHR is one 
component that contributes to the enhanced cell cycle progression promoted by myr PKB. 
 
4.4 Enhanced Th1 and Th2 cytokine production in myr PKB CD4+ T cells 
T cell growth and apoptosis are highly dependent on various cytokines. To better understand 
why myr PKB T cells could proliferate after addition of CsA, we first surveyed the production 
of IL-2, which is an important growth factor in T cell activation and in an autocrine fashion 
regulates the expression of the high affinity IL-2R (235,236). We found that surface 
expression of the IL-2Ra -chain (CD25) in CD3-stimulated wt cells was downregulated to 
levels  found in unstimulated  cells  when CsA was  added to the cultures. In contrast, a higher  
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Figure 10. Active PKB enhances cell cycle progression. A and B, Wt and myr PKB CD4+ (A) and CD8+ (B) T 
cells labeled with CFSE were stimulated with anti-CD3 mAb only or with anti-CD3 plus anti-CD28 mAbs for 2 
or 3 days as indicated. Cell division was analyzed by FACS gating on viable cells on the basis of forward and 
side scatter characteristics. Numbers at the top of histograms indicate the number of cell divisions undergone. 
Panels on the right give the percentage of wt and tg cells that have undergone the indicated numbers of cell 
divisions. C, Faster cell cycle entry of tg CD4+ T cells. CFSE-labeled CD4+ T cells from wt and tg mice were 
activated with plate-bound anti-CD3 mAb for 12 or 18 hrs and then cultured without further stimulus until 24 or 
48 hrs. Cell division was determined as described above. D, Myr PKB positively regulates the expression of cell 
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cycle regulators. Wt and tg CD4+ T cells were stimulated by TCR/CD3 ligation for the time periods indicated, 
and the expression of cyclin D3 and B1 proteins in total cell extracts was analyzed by Western blot. E, Enhanced 
phosphorylation of FKHR in tg T cells. Western blot analysis of pFKHR levels in CE and NE from wt and tg 
CD4+ T cells 8 hrs after stimulation with anti-CD3 mAb (5 mg/ml; upper panels). n.s., Nonspecific loading 
control. The lower panels show expression of endogenous (end) and tg PKB in CE and NE from unstimulated wt 
and myr PKB tg CD4+ T cells (233). 
 
percentage of myr PKB CD4+ T cells still expressed high levels of CD25 in the presence of 
CsA (data not shown). This suggested that myr PKB signaling allows sufficient production of 
IL-2 in the presence of CsA, thus maintaining proliferation. Indeed, as shown in Fig. 11, myr 
PKB CD4+ T cells produced significant amounts of IL-2 when only low TCR signals were 
provided and when CsA was administered. The amounts of IL-2 produced under these 
conditions, therefore, would be sufficient for myr PKB T cells to induce high affinity IL-2R 
and to sustain expansion. In contrast, IL-2 production of wt cells was only obvious when 
CD28 costimulatory signals were provided in addition to low TCR engagement, and under 
these conditions IL-2 production was completely ablated by CsA treatment. 
Furthermore, under the same stimulatory conditions we determined the production of 
other cytokines. We found that besides IL-2, other Th1 cytokines, such as IFN-g and TNF-a, 
and notably also Th2 cytokines such as IL-4 and IL-5 were increased in cultures from myr 
PKB CD4+ T cells, even in the presence of CsA (Fig. 11). As RNase protection assays 
revealed that mRNAs for other Th2 cytokines, including IL-10 and IL-13, were also enhanced 
after TCR/CD3 stimulation (data not shown), myr PKB has an overall positive regulatory 
effect on Th1 and Th2 cytokine production.  
 
4.5 Active PKB impairs nuclear translocation of NFAT proteins 
T cell activation involves induction of the transcription factors NFATc1 and NFATp, which 
play important roles in cytokine gene induction, Th cell differentiation, and apoptosis (180, 
181). Sustained mobilization of intracellular Ca2+ ion triggered by TCR engagement activates 
calcineurin, which, in turn, dephosphorylates the phosphoserine residues in the NFAT 
homology region of NFATs and unmasks the NLS, resulting in their entry into the nucleus. In 
view of the effects of myr PKB on partial resistance to CsA treatment in proliferation and 
cytokine production, we examined whether this phenotype could be linked to increased or 
constitutive activation of NFAT proteins. As shown in Fig. 12A, NE and CE of CD4+ T cells 
from myr PKB and wt mice stimulated with anti-CD3 mAb alone or anti-CD3 plus anti-CD28
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Figure 11. Myr PKB promotes the production of Th1 and Th2 cytokines. CD4+ T cells from wt and tg mice 
were left unstimulated or were treated with anti-CD3 mAb (1 mg/ml) without or with CD28 costimulation (5 
mg/ml) in the presence or the absence of CsA (100 ng/ml). Secretion of the indicated cytokines was determined 
after 24 hrs of culture (233).  
 
 
mAbs in the absence or the presence of CsA were analyzed by Western blot for nuclear 
translocation of NFATc1. Eight hours after activation, most induced NFATc1 protein in wt 
CD4+ T cells was translocated to the nucleus, and nuclear entry was clearly abolished in the 
presence of CsA. Strikingly, whereas in cytoplasmic extracts of myr PKB CD4+ T cells, 
NFATc1 induction after anti-CD3 and anti-CD3 plus anti-CD28 costimulation was obvious, 
nuclear translocation of NFATc1 was hardly detectable (Fig. 12A, upper panel). At earlier 
time points of activation, e.g., at 4 hrs (data not shown), nuclear translocation of NFATc1 
could also not be detected and was drastically diminished even 16 hrs after activation (Fig. 
12A lower panel).  
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Figure 12. Myr PKB impairs nuclear accumulation of NFAT proteins. (A) Wt and tg CD4+ T cells were 
stimulated with anti-CD3 mAbs alone or in combination with anti-CD28 mAbs with or without CsA (100 ng/ml) 
for 8 hrs (upper panel) or 16 hrs (lower panel). NE and CE were analyzed for nuclear translocation of NFATc1 
in Western blot. (B) Wt and tg CD4+ T cells were stimulated with anti-CD3 mAbs alone or in combination with 
anti-CD28 mAbs with or without CsA (100 ng/ml) for 4 hrs. CE and NE were probed for NFATp activation and 
nuclear localization (233). 
 
To test whether this intriguing effect of myr PKB on nuclear shuttling was restricted to 
NFATc1, we examined NFATp activation (Fig. 12B). Similarly, although induction of 
NFATp in the cytoplasm was evident, nuclear translocation of NFATp was hardly detectable 
in myr PKB CD4+ T cells, similar to the blockade seen in CsA-treated wt cells. Thus, myr 
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PKB promotes proliferation and cytokine production in T cells despite immensely diminished 
nuclear levels of NFATc1 and NFATp. 
 
4.6 Enhanced nuclear levels of p-p38, pJNK, and pGSK3 in myr PKB T 
cells 
 
As phosphorylation and dephosphorylation are the basis of NFAT translocation and 
subsequent gene expression, we examined the activities of JNK, p38, and GSK3, kinases that 
have been implicated in the regulation of cytoplasmic-nuclear shuttling of NFAT proteins. In 
particular, overexpression of GSK3 has been shown to significantly reduce nuclear import, 
whereas inhibition of GSK3 slows nuclear export of NFATc1 (195). As shown in Fig. 13A, 8 
hrs after TCR/CD3 activation, phosphorylated GSK3 is clearly detectable in cytoplasmic and 
 
          
   
 
Figure 13. Active PKB enhances phosphorylation of MAPKs, p38 and JNK, and of GSK3. (A) Wt and tg 
CD4+ T cells were cultured in medium only or were activated with anti-CD3 mAb (5 mg/ml) for 8 hrs. The level 
of phosphorylation of the indicated kinases in CE (left panel) and NE (right panel) was analyzed by Western blot 
using phospho-specific Abs. (B) Inhibition of MAPKs and PI3K does not lead to higher nuclear localization of 
NFATc1. Wt and tg CD4+ T cells were stimulated with anti-CD3 mAb for 4 hrs in the absence or the presence 
of the kinase inhibitors, PD98059 (PD), SB202190 (SB), LY294002 (LY), or staurosporine (stau), and NE was 
analyzed for NFATc1 nuclear translocation (233).  
 
nuclear extracts of myr PKB T cells, but is detected only very weakly or not at all in case of 
cytoplasmic  and  nuclear extracts of wt cells. This  correlates  with myr PKB being located in  
the nucleus (Fig. 10E) and published data that active PKB can phosphorylate GSK3, thereby 
leading to its inactivation (237). However, although inactivation of GSK3 by phosphorylation 
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through PKB should foster nuclear retention of NFAT, the opposite, namely, grossly 
diminished nuclear NFATc1 or NFATp, was detected in myr PKB T cells. We therefore 
analyzed cytoplasmic and nuclear levels of active JNK and p38, which by rephosphorylating 
NFAT would induce its nuclear extrusion. As shown in Fig. 13A, myr PKB T cells elicit 
elevated levels of phosphorylated p38 and JNK proteins compared with wt cells upon 
stimulation. These data suggest that rephosphorylation of NFAT by these kinases could be 
involved in the altered cytoplasmic-nuclear shuttling of NFAT in myr PKB T cells. 
 
4.7 Inhibition of MAPK/SAPK and phosphatidylinositol 3-kinase (PI-3K) 
pathways fails to repair the altered nuclear shuttling of NFATc1 
In view of the reported involvement of JNK (197), p38 (198), and PI-3K (226) in opposing 
nuclear translocation of NFAT and our observation regarding higher pJNK and p-p38 levels 
in myr PKB T cells, we studied whether inhibition of these signaling pathways could repair 
the alteration. For this purpose we treated cells with the pharmacological reagents PD98059, 
SB202190, and LY294002, inhibitors of MAPKs and PI3K, respectively, as well as with 
staurosporine, a broad spectrum inhibitor of kinases. The concentrations of inhibitors used in 
these experiments clearly blocked induction of CD25 expression at 4 hrs of stimulation, the 
time point when protein extracts were prepared, and also inhibited proliferation when 
measured by [3H]-thymidine incorporation at 24 hrs, indicating that they effectively blocked 
the respective kinases (Fig. 14A & B). As none of these inhibitors led to higher nuclear 
accumulation of NFATc1 (Fig. 13B), the deficiency in nuclear NFATc1 in myr PKB CD4+ T 
cells is regulated by mechanisms not involving PI3K or the MAPKs, extracellular signal-
regulated kinase (ERK), p38, and JNK. 
 These observations indicated that the negative regulation of NFATs in myr PKB 
CD4+ T cells could have something to do with the constitutively active PKB. As PKB is a 
serine threonine kinase it could be possible that it directly regulates serine phosphorylations 
on NFAT by physically associating with it. We therefore hypothesized whether PKB itself 
could act as NFAT kinase and investigated its direct interaction with NFATc1. 
Immunoprecipitation experiments, as shown in Fig. 15A, clearly detected in vivo association 
of pPKB with NFATc1 in cytoplasmic extracts from tg CD4+ T cells. To confirm that this 
interaction in tg T cells is not due to overexpression of PKB but also occurs in wt T cells we 
analyzed  PKB and  NFAT  interaction by  immunoprecipitation studies  with  anti-pPKB and  
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Figure 14. Specificity of the kinase inhibitors in downregulation of CD25 and inhibition of proliferation. 
(A) Inhibition of the early activation marker CD25. Wt and tg CD4+ T cells were stimulated with anti-CD3 mAb 
for 4 hrs in the absence or the presence of the kinase inhibitors PD98059 (PD), LY294002 (LY), SB202190 
(SB), or staurosporine (stau), and expression of CD25 was analyzed by FACS. (B) Inhibition of proliferation in 
the presence of kinase inhibitors. Purified CD4+ T cells from wt and tg mice were cultured in medium only or 
stimulated with plate-bound anti-CD3 mAb (CD3) at a concentration of 10 mg/ml in the presence or the absence 
of the indicated kinase inhibitors. [3H]thymidine incorporation was measured 24 hrs after initiation of cultures. 
Data show averages from triplicate cultures of two wt and tg mice each. 
 
 
anti-PKB Abs in unstimulated and stimulated wt T cells (Fig. 15B). In unstimulated wt T 
cells, significant coprecipitation of NFATc1 with PKB could only be detected with anti-PKB, 
but not with anti-pPKB, Abs. This probably reflects the minute amounts of active PKB 
present in unstimulated T cells, as in stimulated wt cells immunoprecipitation with anti-pPKB 
Abs also resulted in pull-down of NFATc1. Together these data show that transgenic PKB as 
well as endogenous PKB interact with NFATc1.  
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Figure 15. PKB coprecipitates with NFATc1. (A) Cytoplasmic protein extracts from unstimulated myr PKB 
CD4+ T cells were immunoprecipitated with either anti-phospho-PKB or anti-NFATc1 Abs. Immune complexes 
were resolved by Western blot and probed for interaction with NFATc1 and pPKB, respectively. (B) Interaction 
of NFATc1 with endogenous PKB in unstimulated and stimulated (5 mg/ml anti-CD3 mAb for 4 hrs) wt CD4+ T 
cells was analyzed in immunoprecipitation assays. Anti-Lamin A Ab was used to control the specificity of the 
interaction (233). 
 
4.8 Myr PKB impairs TCR-induced nuclear translocation of RelB and NF-
kBp65, but not NF-kBp50, proteins 
Next we investigated whether the striking effect on nuclear translocation is confined to NFAT 
proteins or also occurs for members of the NF-kB family, which in various cell systems and 
with different stimuli have been shown to become activated via PKB (238, 239). Similar to 
NFAT analysis, CE and NE from wt and myr PKB CD4+ T cells stimulated in the presence or 
the absence of CsA were tested for nuclear translocation of NF-kBp50 and p65 proteins. 
Induction of cytoplasmic NF-kBp50, nuclear translocation, and inhibitory effects of CsA on it 
were similar for both wt and myr PKB CD4+ T cells (Fig. 16A). However, in strong contrast 
to NF-kBp50, nuclear translocation of NF-kBp65 in the case of myr PKB CD4+ T cells at 16 
hrs of activation was markedly diminished, with nuclear NF-kBp65 levels similar to those in 
unstimulated or CsA-treated wt cells. Because of this differential effect of myr PKB on NF-
kB subunits, we investigated translocation of RelB, another member of the NF-kB family. As 
shown in Fig. 16B, in resting cells and in response to both stimulation with CD3 alone and 
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with CD3 plus CD28, no nuclear RelB could be detected in myr PKB CD4+ T cells. Again, 
this is in stark contrast to wt cells, which showed the expected induction of RelB protein after 
TCR engagement. In repeated experiments nuclear levels of NF-kBp65, RelB, and NFAT 
proteins were always drastically diminished, but not completely absent, indicating that nuclear 
shuttling is not completely shut off, but is down-regulated to a major extent.  
 
   
 
Figure 16. Myr PKB diminishes nuclear translocation of NF-kB subunits p65 and RelB. A and B, Western 
blot analysis of NF-kBp50, p65, and RelB in CE and NE from wt and tg CD4+ T cells stimulated as described in 
Fig. 12. NF-kBp50 and p65 expression is shown for cells stimulated for 8 hrs (A), and RelB expression is shown 
for cells 4 hrs after activation (B). n.s., Nonspecific loading control. (C) Similar degradation of IkBa after 
TCR/CD28 stimulation. Wt and tg CD4+ T cells, pretreated with cycloheximide for 15 min, were stimulated 
with anti-CD3 plus anti-CD28 mAbs for the time periods indicated. Whole cell extracts were analyzed for IkBa 
degradation. Protein loading was controlled by actin expression (Fig. 16C was provided by Na Shin-Young, AG: 
Bommhardt) (233). 
 
As activation of NF-kBp65 and RelB, but not of NF-kBp50, proteins is regulated via 
IkBa proteins, we compared the degradation of IkBa in wt and tg T cells. As shown in Fig. 
16C, degradation of IkBa after CD3/CD28 stimulation in myr PKB CD4+ T cells was only 
slightly reduced. This suggests that myr PKB-mediated mechanisms other than targeting 
IkBa degradation are the major factors in the substantial loss of nuclear NF-kBp65 and RelB 
proteins.  
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Part II. Effect of PKB on early thymocyte development: crosstalk 
between PKB and calcineurin signaling 
4.9 Generation of transgenic mice  
 
To study the putative role of PKB in regulating CN signalling during early thymic 
development, we analysed mice double-transgenic for active PKB (137) and a constitutively 
active version of the large CN subunit A, designated as ∆Cam (230).  ∆Cam lacking CN’s 
calmodulin binding and autoinhibitory domains was expressed in early thymocytes under 
control of the proximal p56lck promoter (Fig. 17A). Compared to the expression of 
endogenous CN in wt mice, expression of ∆Cam was elevated about twentyfive to thirty fold 
in the ∆Cam tg mouse line used for all further analyses (Fig. 17B). ∆Cam mice were crossed 
with mice expressing a myristoylated constitutively active version of human PKBa (myr 
PKB) under control of the human CD2 promoter, leading to high level expression of active 
PKB in ∆Cam/PKB DN thymocytes (Fig. 17C).  
  
                                        
 
Figure 17. Generation of calcineurin A/myr PKB double transgenic mice. (A) Schematic representation of 
the injection fragment used to generate calcineurin A transgenic mice. The human calcineurin A catalytic subunit 
containing a deletion of the calmodulin binding and autoinhibitory domain (∆Cam) was cloned under the control 
of the proximal p56Lck promoter and CD2 locus control region (LCR). The polyadenylation site was provided by 
a 2.1 kb fragment of the human growth hormone gene. (B) RT-PCR analysis of calcineurin expression in CD4-
CD8- double negative (DN) cells of wild type, PKB tg, ∆Cam tg and ∆Cam/PKB double tg mice. PKB tg mice 
express a constitutively active form of human PKBa (myr PKB) under the human CD2 promoter. cDNA was 
serially diluted and actin expression was used to control amounts of cDNA applied. (C) Expression of 
phosphorylated active PKB, total PKB and actin, serving as loading control, was analyzed in isolated DN cells of 
∆Cam and ∆Cam/PKB double tg mice by western blot. The lower PKB band represents endogenous PKB (end), 
the upper band transgenic (tg) PKB.    
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Phenotypically, ∆Cam mice did not show any outward abnormality but the total 
cellularity in all the lymphoid organs was severely reduced (Fig. 18). Analysis of thymic 
cellularity shows that compared to wt littermate control mice, ∆Cam mice exhibited on 
average a twenty five fold reduction in the number of thymocytes. Reduction in cellularity 
was also prominent in the lymph node (6 to 7 fold) and spleen (nearly 3 fold) compared to 
control mice. Although the CD4 to CD8 ratio remained similar, there was a sharp decrease in 
the percentage and absolute numbers of both cell types in case of ∆Cam mice. The ratio of T 
verses B cells in LN and spleen and the number and ratio of immature to mature B cells in 
spleen were not significantly altered (data not shown). 
 
 
   
 
Figure 18. Reduced cellularity in the lymphoid compartment of ∆Cam mice. Thymocytes (upper panel), 
lymph node cells (middle panel) and splenocytes (lower panel) from wt and ∆Cam mice were stained for CD4 
and CD8 surface expression. Numbers atop each plot represent total cellularity and numbers within plots give the 
percentage of the individual subsets. Bar diagrams to the right of each panel show absolute cell numbers for 
indicated organs from wt and ∆Cam tg mice. Data shown represent 7-14 individual mice analyzed per organ. 
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4.10  PKB rescues the block in early thymocyte development induced by 
constitutively active calcineurin 
 
Analysis of thymocyte sub-populations revealed a drastic loss in DP cells (5% versus 85%) 
and a marked increase in the percentage of DN cells. The impact of ∆Cam on thymic 
cellularity was already obvious in newborn mice indicating that the loss in DP thymocytes is 
due to a block in early thymocyte differentiation (Fig. 19A & B).  
Further characterisation of the DN population into DN1-4 subsets revealed that almost 
90% of ∆Cam DN thymocytes are CD25+CD44- DN3 cells. Therefore, the loss of DP cells in 
∆Cam mice is due to a developmental arrest at the transition from DN3 to DN4 cells (Fig. 19 
C). Strikingly, simultaneous expression of myr PKB largely restored thymic cellularity, 
allowed efficient T cell maturation and significantly alleviated the DN3 arrest in ∆Cam mice, 
which resulted in a phenotype closely resembling to that of littermate controls (Fig. 19A-C). 
Thus, active PKB releases the DN3 to DN4 transitional block, presumably by counteracting 
CN-induced downstream signalling events including activation of NFAT proteins.  
To prove the observed dramatic effect in term of rescue of the thymic phenotype is 
specific to PKB activity or just a mere transgenic artefact, we generated ∆Cam/PKB double tg 
mice with a second PKB tg line (PKB5). Results from the thymic analysis of ∆Cam/PKB5 
double tg mice were similar to that of ∆Cam/PKB2 double tg mice (Fig. 20A & B). These 
observations argue that the effective rescue of DN3 cells and ultimately the thymic phenotype 
in ∆Cam mice is mediated via active PKB. 
 
4.11 Phenotype of ∆Cam and ∆Cam/PKB DN3 cells  
To understand the molecular mechanisms whereby myr PKB can antagonize the 
differentiation block imposed by active CN, we first investigated several surface antigens that 
are modulated during progression from DN3 to DP cells. Analysis of CD4-CD8-CD25+ DN3 
cells showed that a higher percentage of cells exhibited enhanced expression of CD2 and CD5 
in ∆Cam tg mice compared to DN3 cells from PKB tg mice or wild type littermates (Fig. 21 
A). The elevated expression of these two markers indicates that the ∆Cam DN3 cells have 
received at least part of the activation signal essential during DN3 to DN4 transition. The 
majority of ∆Cam DN3 cells also showed lower levels of HSA (CD24) whereas IL7R 
expression was similar to control cells. Cell size is an indicator of the cycling status of cells. 
Larger size cells are either cycling or are ready to cycle and smaller size cells are non-cycling 
cells. But there was no difference in the cell size from ∆Cam or ∆Cam/PKB DN3 cells 
compared  to the  control DN3 cells  (Fig. 21A  lower  panel). Notably, myr PKB  reverted the 
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 expression of the surface antigens in ∆Cam DN3 cells towards the “normal” phenotype 
indicating that in the presence of myr PKB ∆Cam DN3 cells underwent normal 
differentiation.  
 
  
 
Figure 19. Active PKB rescues thymocyte development in ∆Cam tg mice. (A) Distribution of thymocyte 
subsets in wt, PKB tg, ∆Cam tg and ∆Cam/PKB double tg mice, either aged 6 weeks (upper panel) or 1 day 
(lower panel). Single cell suspensions of thymocytes were stained for CD4 and CD8 surface expression and 
analyzed by flow cytometry. Numbers give the percentage of cells in the corresponding thymocyte subset. 
Thymocyte cellularity for individual mice is provided at the top of each plot. (B) Absolute cell numbers and 
percentages of DN and DP cells in wt, PKB tg, ∆Cam tg and ∆Cam/PKB double transgenic mice. Data shown 
represent 10-24 individual mice per group. (C) PKB rescues the developmental block at the DN3 stage induced 
by constitutively active calcineurin. DN thymocytes from the four indicated mouse strains were analyzed for 
CD25 and CD44 expression after gating on cells negative for CD4 and CD8 expression. The percentages of the 
individual DN1-DN4 subsets are indicated in the quadrants.  
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T cell development involves several processes that occur in different anatomic sites 
within the thymus. Therefore, thymocytes must have the ability to respond to signals received 
from stromal cells and adopt either adhesive or motile behavior (240). Cell adhesion 
molecules play an important role in these processes and thymocytes employ various integrins 
at different developmental stage for adhesion or motility. Analysis of expression of integrins 
exhibited much higher expression of LFA-1 (CD11) and CD18 (integrin b2 chain) on ∆Cam 
DN and DP thymocytes compared to wt or PKB tg controls (Fig. 21B, left and middle panel). 
Expression of CD49d (integrin a4 chain) was also higher in ∆Cam mice than in control mice. 
Active PKB only partially reduced the expression level of all these integrins in the double tg 
mice (Fig. 21B, left, middle and right panel), indicating that PKB has only little influence in 
the regulation of these integrins.     
 
   
 
 
Figure 20. Rescue of thymic phenotype in ∆Cam/PKB5 double tg mice. (A) Distribution of thymocyte 
subsets in wt, PKB5 tg, ∆Cam tg and ∆Cam/PKB5 double tg mice, aged 6 weeks. Single cell suspensions of 
thymocytes were stained for CD4 and CD8 surface expression and analyzed by flow cytometry. Numbers give 
the percentage of cells in the corresponding thymocyte subset. Thymocyte cellularity for individual mice is 
provided at the top of each plot. (B) PKB5 rescues the developmental block at the DN3 stage induced by 
constitutively active calcineurin. DN thymocytes from the four indicated mouse strains were analyzed for CD25 
and CD44 after gating on cells negative for CD4 and CD8 expression. The percentages of the individual DN1-
DN4 subsets are indicated in the quadrants.  
 
4.12 Normal Apoptosis and cell cycle in ∆Cam DN thymocytes 
The reduced thymocyte cellularity in ∆Cam mice could be due to; either increased apoptosis, 
reduced cell cycle or a combination of both. To clarify the effect of ∆Cam on the survival of 
DN cells, we examined levels of the anti-apoptotic protein Bcl2 and of apoptosis by annexin V 
staining. Bcl2 expression has been described to be high in DN cells and low in most DP cells 
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(241). Accordingly, DN3 cells of wt and myr PKB tg mice showed two populations with 
higher and lower levels of Bcl2 (Fig. 22A). ∆Cam expressing DN cells only showed one 
population with  very high Bcl2 levels that  were even above those detected in control mice. In  
 
      
 
    
B 
 
 
Figure 21. Active PKB reverses the effects induced by ∆Cam in DN cells. (A) Histograms show expression of 
CD2, CD5, HSA, IL7R and cell size of CD25+CD44- DN3 cells of wt, PKB, ∆Cam and ∆Cam/PKB tg mice. 
Numbers in each histogram represent the percentage of cells showing medium and high expression of each 
marker or in case of FSC the mean fluorescence intensity (MFI). (B) Analysis of integrin expression on DN and 
DP thymocytes. Thymocytes from 6 weeks old mice in each group were surface stained for CD4, CD8 and 
various integrins. Plots show analysis of LFA-1 (left), CD18 (middle) and CD49d (right) expression on DN and 
DP thymocytes.  
 
presence of myr PKB, Bcl2 expression was intermediate between ∆Cam and wt DN3 cells. In 
addition, a population with lower Bcl2 expression was now detectable as found in wt cells, 
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presumably representing those cells that have progressed in differentiation towards the DN4 
stage. Annexin V staining did not show any drastic difference in apoptosis between ∆Cam 
mice to that of the ∆Cam/PKB double transgenic or the control mice. Only an about 2-fold 
increase in apoptosis of DN3 cells from ∆Cam mice was detected compared to the control or 
double tg mice (Fig. 22B). Thus, inhibition of DN3 progression by ∆Cam is accompanied by 
strong induction of Bcl2 and only slightly enhanced apoptosis of DN3 cells.  
 The cell cycle profile of ∆Cam DN cells also did not show any drastic abnormality. 
Whereas in the control and in the double tg mice around 15% of DN cells were in the cycling 
(S+G2+M) phase, it was slightly reduced (11%) in case of ∆Cam DN cells (Fig. 22C). 
Combinedly these data show the defect in ∆Cam thymocyte development is not because of 
dysregulated apoptosis or cell cycle but due to some other anomalies. 
 
  
             
 
 
Figure 22. Apoptosis and cell cycle in ∆Cam DN thymocytes. (A) Higher intracellular Bcl2 expression in DN 
thymocytes from ∆Cam compared to ∆Cam/PKB, wt and PKB tg mice. (B) Profiles of Annexin V stained DN3 
thymocytes in each group. Numbers in each histogram indicate percentage of Annexin V positive cells. (C) Cell 
cycle profile of ∆Cam tg mice. Isolated DN thymocytes from indicated mice were stained with PI and were 
analyzed for cell cycle status. M1 and M2 gates represent cells at G0/G1 (non cycling) and S/G2/ and M phases 
(cycling) of cell cycle, respectively. Numbers in each plot represent percentage of cells in noncycling and 
cycling stages. 
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4.13 ∆Cam DN3 cells are normal in CD3e  chain expression 
DN3 to DN4 transition during thymocyte development is dependent on signaling from the 
pTCR/CD3 complex. Mutation or deletion of various CD3 complex components has been 
shown to block thymocyte development at the DN3 stage (242-244). We therefore reasoned to 
explore whether thymocytes from ∆Cam mice have any abnormality in the signaling from the 
pTCR/CD3 complex. Intracellular staining for of CD3e in DN3 cells from ∆Cam mice 
showed a similar level of expression as found for control and double tg DN3 cells (Fig. 23A, 
upper panel). Also, there was no apparent difference in CD3e expression in the DN4 cells 
from each group (Fig. 23A, lower panel). Simultaneously when we looked at downstream 
signaling molecules we found phospho ERK levels were clearly increased indicating 
enhanced pTCR/CD3 signaling (Fig. 23B).  
 
 
 
 
Figure 23. ∆Cam DN3 cells show normal CD3e chain expression but enhanced ERK activation. (A) 
Expression of CD3e chain in DN3 and DN4 cells from wt, PKB, ∆Cam and ∆Cam /PKB double tg mice. 
Numbers in each histogram indicate percent of thymocytes expressing high level of CD3e. (B) Higher 
phosphoERK level in ∆Cam DN thymocytes. Western blot analysis of WCE from isolated DN thymocytes from 
indicated mice for pERK expression. Actin was used to show protein-loading control. 
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4.14 Myr PKB rescues Rag1 and icTCRb  chain expression in ∆Cam DN3 
cells 
 
Based on the finding that despite up-regulation of certain surface molecules and enhanced 
ERK activation, ∆Cam DN3 cells failed to develop into DN4 cells, we suspected defects in 
expression of the TCRb chain. FACS analysis showed that only 0.17% of ∆Cam DN3 cells 
expressed high levels of icTCRb compared to 13-15 % in wt or PKB tg DN3 cells (Fig. 24A).  
Likewise, whereas almost all DP cells of wt and PKB tg mice were positive for icTCRb, only 
43% of the few DP cells arising in ∆Cam mice showed high levels of icTCRb. Strikingly, 
simultaneous expression of myr PKB increased the percentage of ∆Cam DN3 cells expressing 
icTCRb chain by 20-fold and restored icTCRb expression in DP cells to normal levels. Thus, 
active PKB reverts the defects in icTCRb chain expression imposed by active CN.  
 
      
 
 
Figure 24. Expression of active PKB significantly enhances icTCRb  and Rag1 expression in ∆Cam DN 
cells. (A) Expression of intracellular TCRb (icTCRb) in DN3 and DP cells from wt, PKB, ∆Cam and 
∆Cam/PKB double tg mice. Numbers in each histogram indicate the percentage of thymocytes expressing 
icTCRb. (B) Myr PKB rescues the defect in Rag1 expression imposed by ∆Cam. Whole cell extracts of 
unstimulated DN thymocytes were fractionated by SDS-PAGE and immunoblotted with Rag1 antibody. Protein 
loading was controlled by actin antibody. (C) The ∆Cam induced block of Rag1 expression is transcriptional. 
Total RNA from unstimulated DN thymocytes was used for analysis of RAG1 gene expression by RT-PCR. b-
actin RT-PCR shows equal quantity of cDNA used. 
 
To dissect the defect in TCRb chain expression, we analysed the expression of Rag1 
protein, which is essential for the recombinatorial rearrangements at the TCRb chain locus. In 
∆Cam DN cells we detected extremely low Rag1 protein levels. However, Rag1 expression 
became normal when PKB was expressed simultaneously (Fig. 24B). Further RT-PCR studies 
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revealed the absence of Rag1 protein expression in ∆Cam DN cells to be linked with reduced 
Rag1 mRNA levels (Fig. 24C), suggesting that active CN regulates RAG1 expression via 
transcriptional and/or post-transcriptional mechanisms. Again, in PKB/∆Cam DN cells Rag1 
mRNA levels approached those found in wt or PKB tg cells (Fig. 24C). In conclusion, ∆Cam 
induces a block in early thymocyte differentiation by drastically reducing RAG1 expression 
and preventing efficient TCRb gene rearrangement. Active PKB either by directly acting on 
CN, its targets or some unknown proteins, overcomes the negative regulatory effects induced 
by ∆Cam, allowing DN3 cells to efficiently express Rag1, rearrange TCRb chains and to 
progress in differentiation to DP cells. 
 
4.15  TCR transgenes can partially overcome the ∆Cam-mediated DN3 arrest  
Since, inefficient or lack of pre-TCR assembly due to defective Rag1 expression seems to be 
a major defect in ∆Cam DN3 cells, we analysed whether a functionally rearranged tg TCR 
will be able to overcome the differentiation block. Therefore, we crossed ∆Cam mice with 
OT1 TCR tg mice and analysed cellularity and thymocyte subsets in these ∆Cam/OT1 double 
tg mice. As shown in Fig. 25 and Table 3 below, expression of the OT1 tg TCR increased the  
 
                                     
 
Figure 25. Expression of the transgenic OT1 TCR is not sufficient to rescue the thymic phenotype in 
∆Cam tg mice. FACS profile of CD4 and CD8 stained thymocytes from 6 weeks old OT1 and ∆Cam/OT1 mice. 
Numbers indicate the percentage of DP cells (upper panel). Histograms (lower panel) show expression levels of 
the OT1 TCR specific Vb5 and Va2 chains in DN3 thymocytes from OT1 and ∆Cam/OT1 mice. 
 
Table 3. Effect of OT1 TCR transgene expression on thymic phenotype of ∆Cam mice 
 
n = 4   OT1   ∆Cam /OT1  ∆Cam 
Total (x 106)  157.5 (± 14.6)  14.0 (± 20.0)  3.3 (± 2.5) 
 
% DP   79.2 (± 0.9)  30.0 (± 19.8)  5.4 (± 1.5) 
 
% DN3 of DN  19.4 (± 1.8)  86.2 (± 4.2)  88.4 (± 1.1) 
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percentage of DP cells in ∆Cam mice maximally about 6-fold and the total cell number about 
3 fold. Concerning expression of the OT1 TCR specific Vb5 and Va2 chains, we observed 
that in the double tg mice a higher fraction of DN3 cells expressed the tg TCR chains 
compared to OT1 DN3 cells but in overall the percentage of DN3 cells within the total DN 
population was not significantly altered. In comparison to the dramatic rescue of maturation 
of DP cells and thymic celluarity by active PKB, we concluded that expression of a pre-
rearranged TCR alone supports but is insufficient to completely overcome the DN3 arrest 
induced by ∆Cam. This implies that active PKB evokes mechanisms in addition to controlling 
RAG1 and TCRb chain expression. 
4.16 CsA treatment releases the CN-induced DN3 block in differentiation 
Since our previous studies suggested a direct interaction between PKB and NFATs (233), we 
decided  to focus on NFAT regulation in  the  double  tg  ∆Cam/PKB mice. First, we analyzed 
            
Figure 26. Inhibition of calcineurin by CsA  allows normal differentiation of ∆Cam DN3 cells. (A) Thymic 
lobes from newborn ∆Cam and wt mice were cultured without or with CsA (100 ng/ml) for 4 days. Thymocytes 
were stained for CD4 and CD8 and thymocyte subsets were determined by FACS analysis. Numbers at the top of 
each plot represent total cellularity. (B) Thymocytes from lobe cultures described in (A) were analyzed for 
icTCRb chain expression. Histograms are gated on total DN cells and the numbers in each histogram indicate 
percentage of icTCRb positive cells.  
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whether inhibition of CN and therefore inhibition of NFAT activation, would restore T cell 
differentiation in ∆Cam mice. For this purpose we cultured newborn thymic lobes from ∆Cam 
and wild type mice in the presence or absence of CsA, an efficient inhibitor of CN-driven 
NFAT activation. As shown in Fig. 26A, CsA treatment, in contrast to untreated ∆Cam lobes, 
led within 4 days to a 10-fold increase in cellularity and enabled differentiation of DN cells to 
the DP stage (42% versus 0.7% DP in untreated lobes). Likewise, CsA treatment efficiently 
restored high level expression of icTCRb chain in ∆Cam DN cells (Fig. 26B). Thus, inhibition 
of calcineurin/NFAT activity allows normal expansion and differentiation of otherwise 
arrested ∆Cam DN3 cells. 
 
4.17 Myr PKB rescues the thymic phenotype in ∆Cam tg mice by regulating 
NFAT proteins 
In accordance with CN's role in regulating NFAT proteins and PKB's pivotal effects in ∆Cam 
tg mice, we next asked whether myr PKB counteracts the effects induced by ∆Cam by 
inhibition of NFAT activation. Using confocal microscopy, we studied the expression of 
NFATc1 and NFATc3 in DN cells of ∆Cam and ∆Cam/PKB tg mice. Thymocytes were 
stained for CD4 and CD8, and NFAT expression was evaluated in CD4-CD8- cells. As 
evident from Fig. 27A and B, in ∆Cam tg mice NFATc1 expression was very strong in the 
majority (about 80%) of DN cells and only about 20% of cells showed lower levels of 
NFATc1. In NFATc1 high expressing cells NFATc1 was totally nuclear as judged by staining 
of nuclei with DAPI (data not shown). Intriguingly, in ∆Cam/PKB tg mice about 70% of DN 
cells showed lower levels of NFATc1 and only 30% of cells showed nuclear levels as high as 
found in ∆Cam DN cells. Importantly, this inverted ratio of NFATc1hi versus NFATc1lo cells 
corresponded to the expression levels of NFATc1 in DN cells from wt or myr PKB tg mice.  
 Since various NFAT family members seem to play different roles during the 
progressive stages of thymocyte development, we  also studied  the  expression of NFATc3 in 
the respective mouse lines. NFATc3 has been shown to be mainly thymocyte specific. As 
observed for NFATc1, the nuclear load of NFATc3 was very high in almost all DN cells of 
∆Cam tg mice. In stark contrast, NFATc3 expression was low in the majority of DN cells of 
∆Cam mice when myr PKB was present (Fig. 28A). In addition, NFATc3 levels in DN cells 
of ∆Cam/PKB tg mice corresponded to those in DN cells of wild type or PKB tg mice (data 
not shown). From these experiments it is obvious that one pivotal action of myr PKB is the 
reduction of NFATc1 and NFATc3 activation in ∆Cam DN cells. 
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Figure 27. Myr PKB regulates nuclear NFATc1 levels in DN thymocytes. (A) Distribution of NFATc1 in DN 
thymocytes. Confocal images of thymocytes surface stained for CD4 (blue) and CD8 (green) and intracellular 
NFATc1 (red) from wt, PKB tg, ∆Cam and ∆Cam/PKB double tg mice. Arrows indicate representative DN cells 
in each image showing nuclear and cytoplasmic distribution of NFATc1. (B) Proportion of DN cells showing 
varying NFATc1 level. DN cells from each individual mouse were evaluated on the basis of high or low 
NFATc1 levels. Data represent percent of NFATc1hi and NFATc1lo cells from 150-350 DN cells counted for 
each group. 
 
 89 
 
4.18 Higher nuclear level of NFATc1 and NFATc3 in Rag-/- DN3 thymocytes 
 
In Rag k.o. mice thymocyte development is blocked at CD44-CD25+DN3 stage due to 
absence of TCRb rearrangement and the pre TCR signaling. ∆Cam DN3 thymocytes are 
severely deficient in Rag expression and activity. Thus functionally ∆Cam DN3 cells are 
similar to Rag1 ko DN3 cells. Since ∆Cam DN thymocytes (which are mainly DN3) show 
high nuclear NFATc1 and NFATc3 levels, we explored NFAT levels in Rag1 k.o. 
thymocytes. Surprisingly, confocal microscopy showed  high levels of nuclear NFATc1 
whereas  NFATc3  levels were  low  in Rag1 k.o. DN3  cells, although  these cells  definitely  
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Figure 28. NFATc3 nuclear translocation is also regulated by myr PKB. (A) Distribution of NFATc3 in 
representative DN thymocytes from ∆Cam tg and ∆Cam/PKB double tg mice. (B) Confocal images show 
distribution of NFATc1 and c3 in Rag1 ko thymocytes.  
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lack a  functional pre TCR (Fig. 28B). The functional significance and the signals that induce 
NFAT has to be analyzed in future studies.  
4.19 Active PKB induced lymphoma show dysregulation in NFAT nuclear 
translocation 
 
PKB tg CD4+ T cells show a severe reduction in nuclear translocation of NFATc1 and 
NFATp (233). TCR ligation alone or in combination with CD28 costimulation could not 
reverse this effect (Fig. 12A & B). Also in ∆Cam/PKB DN thymocytes the nuclear 
accumulation of NFATc1 and NFATc3 is significantly regulated and this reduction in nuclear 
NFATs is responsible for the rescue of thymic phenotype in the double tg mice. Hence, we 
hypothesized NFATs could be directly phosphorylated by PKB. In vitro kinase assay show 
PKB could infact phosphorylate multiple serine residues in NFATc1 (S.Y. Na, personal 
communication).  
                                     
Figure 29. PKB induced T cell lymphoma exhibits impaired NFAT regulation. Nuclear (NE) and 
cytoplasmic (CE) distribution of NFATc1 and NFATc2 in CD4+T cells from wt mice and electronically sorted 
CD4+ Vb6+ lymphoma cells stimulated with plate-coated CD3e Ab for 4 hrs. 
 
Both NFATs and PKB have been shown to regulate growth and proliferation. From 
our observations in thymocytes and CD4+T cells it is becoming increasingly clear these two 
molecules could play a role in tumorigenesis. In PKB induced lymphomas, which develop in 
myr PKB homozygous mice we suspected that NFAT activation should be altered. Sorted 
CD4+ cells from mono/oligoclonal T cell lymphoma (all positive for Vb6 chain) and 
polyclonal wt type CD4+ T cells were activated with CD3e Ab and analysed for NFATc1 and 
NFATc2 activation. The outcome was exactly similar to that in PKB tg CD4+ T cells. In 
contrast to strong nuclear NFAT localization in wild type CD4+ T cells, only marginal levels 
of nuclear NFATc1 and NFATc2 could be detected in the lymphoma cells (Fig. 29). Thus, 
myr PKB induced CD4+ T cell lymphoma is characterised by nuclear deficiency of NFATc1 
and NFATc2 proteins. 
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5. Discussion 
 
5.1  Myr PKB in T cell activation, cell cycle progression and cytokine 
production 
In this study on the effects of a constitutively active PKB on T cell development and function, 
we demonstrate that myr PKB tg T cells show a marked difference in a number of 
physiological parameters compared to wt T cells. First, they exhibit a distinct advantage in 
proliferation towards weak or suboptimal TCR signals (Fig. 9A & B). Second, proliferation of 
myr PKB tg T cells is significantly resistant to the immunosuppressive agent cyclosporin A 
(CsA) (Fig. 9A & B), an observation which could contribute towards better understanding of 
the phenomena of inflammation and hypersensitivity. Third, myr PKB tg T cells undergo cell 
cycle at a distinctly higher rate than wt T cells (Fig. 10A & B). Fourth, myr PKB tg T cells 
exhibit higher efficiency in production of cytokines of both Th1 and Th2 type and cytokine 
production is also less affected to CsA treatment (Fig. 11). Fifth and most importantly, myr 
PKB tg T cells exhibit all the above mentioned properties independent of CD28 costimulatory 
signals (Figs. 9, 10 & 11). 
CD28 is the primary T-cell costimulatory receptor, the engagement of which is 
necessary for TCR induced proliferation of naive T cells. A number of studies have 
demonstrated that CD28, upon interaction with its ligands B7.1 (CD80) or B7.2 (CD86), is 
able to enhance interleukin-2 (IL-2) synthesis (245,246). One of the key events in T cell 
proliferation is the activation of the IL-2 gene promoter, which includes consensus binding 
sites for multiple transcription factors, like AP-1, NF-kB, NFAT and cAMP response element 
binding protein (CREB). Cooperative interaction between these factors is required for 
efficient IL-2 production. However, PKB tg CD4+ T cells show optimal proliferation to a ten 
fold lower TCR signal to that of wt indicating lower threshold of TCR signaling for activation 
and proliferation.  
Expression of an active gagPKBa construct in T cells was shown to alter T cell 
homeostasis, indirectly influence B cell homeostasis and to promote inflammation in vivo 
(175). T cells from transgenic mice expressing a CA-PKB mutant displayed resistance to a 
variety of apoptotic stimuli (174). PTEN, which inhibits PKB activation, is an essential 
mediator of the CD95 response and a repressor of autoimmunity, as CD95-mediated apoptosis 
was impaired in PTEN heterozygous mice, and T lymphocytes from these mice showed 
reduced activation-induced cell death and increased proliferation upon activation (176, 247). 
PTEN-/- mice were shown to die during embryogenesis as a result of a failure in 
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developmental apoptosis (248,249). Surprisingly, ablation of PKBa by itself does not have 
the severe phenotype, as expected from the phenotypes of PTEN-/- mice or transgenic mice, 
expressing CA-PKB (126). PKBb and PKBg may substitute to some extent for the loss-of-
function of PKBa. However, taken together the role of PKB in cell proliferation and survival 
is rather clear. In this regard, signaling models based on results from Jurkat T-cells may 
underestimate the role of the PI-3K/PKB pathway as these cells are deficient of PTEN 
(250,251) and therefore PKB kinase activity is constitutively active. 
Our observation concerning cytokine production shows, PKB tg CD4+ T cells not 
only produce higher IL-2 in the absence of CD28 costimulation, but also produce higher 
levels of Th1 cytokines like TNF-a and IFN-g and Th2 cytokines like IL-4 and IL-5 
compared to wt CD4+ T cells. Among the Th1 and Th2 cytokines PKB tg CD4+ T cells seem 
to have a bias towards Th1 cytokines as evident from TNF-a and IFN-g production (Fig. 11). 
Implications of this huge production of Th1 cytokines are not yet known.  
CD28 co-stimulation was also shown to directly regulate cell cyle entry and 
progression through the G1 phase in an IL-2-independent manner by downregulation of the 
cyclin-dependent kinase (cdk) inhibitor p27KIP1. Subsequent progression to the S phase is 
mediated via both IL-2 dependent and IL-2 independent mechanisms (252). Cell cycle 
progression is a complex process that is activated by cyclins that associate with catalytically 
active cdks and is inhibited by cdk inhibitors (253). Induction of D-type cyclins occurs during 
G1 phase, induction of cyclin E at the late G1 restriction point, induction of cyclin A at the S 
phase entry and cyclin B1 at the M phase entry. The orderly progression of the cells through 
the cell cycle is controlled by the timely expression of cyclins, the activation of cdk enzymatic 
activity and the subsequent phosphorylation of the relevant substrates. 
Cell division profile from PKB tg CD4+ T cells in response to TCR stimulation in 
absence of CD28 costimulation are very similar to the profiles from wt CD4+ T cells 
stimulated with TCR plus CD28 (Fig. 10A & C). The independence of CD28 costimulation is 
manifested in the higher levels of phosphorylated cyclins D3 and B1 in myr PKB T cells, 
which would contribute to faster entry into the G1 and M phase of cell cycle compared to wt 
cells. PKB has been shown to regulate cell division and cell cycle progression by acting on a 
number of different molecules involved in these processes. Prominent among them are the 
cell cycle inhibitors p21CIP1 and p27KIP1 (162-166). Besides it also regulates the checkpoint 
kinase 1 and 2 (chk1 & 2)  (254,255) and various forkhead transcription factors (234). 
Forkhead proteins are generally nuclear in resting cells and inhibit cell cycle progression at 
the M phase. One of the target genes of forkhead transcription factors is the cdk inhibitor 
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p27KIP1 (256). PKB inactivates forkhead proteins by phosphorylation, facilitates their nuclear 
exclusion and thereby augments entry into M phase and subsequent cell cycle progression. 
Both p27KIP1 and forkhead have been shown to be direct targets of PKB in many different cell 
systems. Accordingly, we observe phosphorylated forkhead protein (FKHR) in the cytoplasm 
of resting myr PKB tg but not wt CD4+ T cells. 
This observation along with the higher TCR sensitivity, increased cytokine production 
and increased levels of phosphorylated cyclins indicate that expression of constitutively active 
PKB replaces CD28 costimulatory signals to a great extent in various T cell functions. Myr 
PKB induced hyperproliferation when complimented with other cell cycle deregulatory 
mechanisms could contribute to the development of various forms of cancer. 
 
5.2    Negative regulation of NFAT and NF-kB by myr PKB 
The most important finding of this study is that the positive effects of myr PKB on T cell 
responses are coupled with a negative regulatory role of myr PKB on the nuclear localization 
of NFAT and NF-kB proteins. As coprecipitation experiments reveal an interaction betweem 
PKB and NFATc1 in vivo (Fig.15), active PKB could modify this transcription factor either 
directly or via some substrate associated within a multiprotein complex. To date we do not 
know whether the functional loss of nuclear accumulation of NFAT proteins is the result of 
inhibition of nuclear import or enhancement of nuclear export. Mutations in the NLS 
sequences of NFATs have been reported to reduce their nuclear localization (185,186). Thus, 
in the simplest scenario, sustained activation of PKB could interfere with unmasking of the 
NLSs and thereby retaining NFAT in the cytoplasm.  
Recently, analysis of the regulation of nuclear shuttling of NFAT proteins has 
identified a number of NFAT kinases that oppose NFAT nuclear translocation, including 
GSK3 and the MAPKs, JNK and p38 (197, 198). However, the exact mechanisms of the 
regulation of NFAT activation and its subcellular localization by these kinases are not 
completely understood. GSK3 itself is a known target of PKB signaling, and phosphorylation 
leads to its inactivation (237). Although we detected higher levels of phosphorylated GSK3 in 
the nucleus of myr PKB T cells compared with wt cells, accumulation of nuclear NFAT was 
reduced, rather than increased. Considering the data on stronger activation of p38 and JNK in 
myr PKB T cells, one possibility could be that phosphorylation of NFAT by these kinases, 
which would foster nuclear extrusion, dominates over nuclear retention signals expected to be 
provided by inactive GSK3. However, in experiments in which activation of MAPKs and PI-
3K was inhibited by pharmacological inhibitors, we did not observe any reversal of the block 
 95 
in nuclear translocation of NFATc1 in tg T cells (Fig 13B). Thus, the enhanced JNK and p38 
activities in myr PKB CD4+ T cells could contribute to the T cell hyper-responsiveness 
without being involved in the regulation of NFATs.  
NFAT proteins are normally thought to be positive regulators of transcription, thereby 
regulating lymphoid homeostasis (257). However, studies from NFAT knockout mice also 
document a negative role of NFAT proteins in T cell function (258-261). In this context, in 
mice doubly deficient in NFATp and NFATc3 Th cells show hyper-responsiveness 
independent of CD28 coengagement (262), similar to our PKB transgenic system in which 
hyper-responsiveness of T cells and enhanced production of Th1 and Th2 cytokines are 
coupled with reduced nuclear NFAT activity. Recently, a direct association of NFATp with 
the histone deacetylase 1 in regulation of the cdk4 promoter has implicated NFAT in the 
down-modulation of immune responses when cells return to a quiescent state (263). 
Furthermore, NFAT has been indicated to be involved in the expression of stage-specific 
cyclins, unveiling a role for NFAT in the regulation of the cell cycle (264). We therefore 
propose that by direct interaction, active PKB regulates NFAT localization and thereby 
partially exerts its positive regulatory role on T cell activation and effector function. The 
modified regulation of subcellular localization of NFAT and other to date unknown proteins 
in cells with constitutively active PKB may contribute to the development of T cell 
lymphomas, as observed in our myr PKB homozygous mice (data not shown) and other 
reports where overexpression of active PKB is associated with tumor development (247, 265, 
266).  
 Our observations concerning myr PKB’s negative regulatory role on NF-kBp65 and 
RelB (Fig.16A & B) are in contrast with studies in which PI-3K/PKB signaling in transient 
transfection systems and using PI3K inhibitors was found to enhance NF-kB activation (155, 
238, 239, 267). Some of these studies point to a possible role for PI-3K/PKB signaling in 
activating the IkB kinase complex and NF-kB trans-activational activities. Phosphorylation 
and ubiquitination-dependent degradation of IkBa, the cytoplasmic inhibitor of NF-kB, via 
the inducible IkB kinase complex (IKK), liberates NF-kB to translocate into the nucleus and 
to transcriptionally activate its target genes, including the IL-2 gene. In Jurkat T cells, PKB 
was also shown to regulate signaling pathways that lead to induction of NF-kB. However, 
PKB was not sufficient by itself to induce NF-kB reporters, since signals from other 
pathways, in particular phorbol ester, the pleiotropic PKC activator, was found to be required, 
implicating a functional PKB-PKC connection (238). In T cells the isotype PKC theta is 
known to selectively activate NF-kB (268, 269). Recently, it has become clear that PKC theta 
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cooperates physically and functionally with PKBa/AKT1 in NF-kB signaling in TCR/CD28 
stimulated T cells (270). Moreover plasma membrane targeting of PKC theta and PKBa 
exerted synergistic transactivation of the IKKb/IkB/NF-kB signaling cascade independent of 
T cell activation (270). Along this line, it was shown that PKB can provide the CD28 
costimulatory signal for RE/AP activation, a region of the IL-2 promoter, known to be 
activated by signals that originate from the TCR and CD28, and known to include NF-kB 
binding sites (239). 
  However, a number of other research groups found no evidence for PI-3K signaling 
in NF-kB activation (271,272). The opposing results probably reflect the use of different 
experimental systems, constructs, and stimuli. In T cells expressing a transgenic gagPKB 
construct, IkB degradation and DNA binding of NF-kB were enhanced compared with those 
in wt cells (174). We assume that the differences between our myr PKB and the gagPKB 
transgenic systems result from differences in temporal and spatial expression levels of active 
PKB. In our transgenic system the role of active PKB seems to entail the down-modulation of 
certain NF-kB and also NFAT responses, rather than enhancing TCR-mediated activation of 
these proteins. Hence, our findings may reflect differences in the overall 
activation/differentiation status of myr PKB T cells compared with wt cells or cell lines 
transiently transfected with active PKB. Our observations thus would reveal the function of 
PKB in down-modulation of transcriptional activities such as might occur when activated T 
cells return to a resting state or during specific differentiation processes.  
To date we do not know how myr PKB affects NF-kBp65/RelB nuclear translocation, 
and a variety of different mechanisms can be envisaged. In addition to the regulation via NF-
kB:IkBa complexes, it is now evident that NF-kB/Rel proteins are regulated post-
translationally via phosphorylation (272) or acetylation events (273). Thus, as the overall 
IkBa degradation in myr PKB T cells was normal, it is likely that myr PKB or one of its 
substrates acts downstream of IkBa degradation to inhibit nuclear translocation of NF-kB. In 
view of altered regulation of NFAT as well as NF-kB family members, it may also be 
possible that myr PKB acts by a similar mechanism on the Rel homology domain, which is 
common in both classes of transcription factors. NF-kBp50 may not be affected, because its 
activation depends on processing of a larger precursor protein and also lacks the C-terminal 
trans-activation domain(s) that might be critical.  
From a host of studies we know that a delicate balance between positive and negative 
regulatory mechanisms determines the specificity and magnitude of immune responses. 
Despite all the above considerations, the novel finding that active PKB is involved in the 
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negative regulation of nuclear transcription factors highlights the role of PKB in processes 
related to the inactivation of gene expression programs through the subcellular localization of 
transcription factors.  
 
5.3  Crosstalk between PKB and calcineurin in modulating early thymocyte 
development 
The precise molecular mechanisms involved in DN3 to DN4 transition during early 
thymocyte development are poorly understood. Pre-TCR signaling and transition of DN to DP 
cells has been shown to involve calcium flux and NFAT signaling (95). Based on our  
previous data that PKB can target NFAT activation (233) in peripheral T cells, here we show 
that PKB is an essential regulator of calcineurin-NFAT signaling in early T cell 
differentiation. We concur with the earlier observation of Hayden-Martinez et al. (212) that 
over-expression of active calcineurin (∆Cam) induces a block at the DN3-DN4 transition with 
a resultant absence of DP cells (Fig.19A & B). Studies from gene deficient mice show a DN3 
to DN4 block could be due to an impairment in pTCR assembly and/or due to a defect in any 
of the molecules in the signaling pathway immediately downstream to pTCR (242-244, 63, 
64, 11, 13, 71, 72). We did not detect any perturbation in CD3e chain expression in DN3, 
DN4 and DP cells arguing against early defects in signaling downstream of the pTCR (Fig. 
23A and data not shown). In fact, ∆Cam DN cells show higher pERK levels compared to 
control or double tg cells (Fig. 23B). We show on molecular terms that the severe block at the 
pre TCR checkpoint is due to defective Rag expression and icTCRb chain formation (Fig. 
24A-C). Since we observed a drastic increase of NFATc1 and NFATc3 expression in DN 
cells of ∆Cam mice, it is obvious that spatial/temporal expression of the individual NFAT 
members must be tightly regulated during b-selection in order to proceed with normal T cell 
development.  
Notably, we were able to directly link PKB signaling with calcineurin/NFAT 
activation in early T cell differentiation since simultaneous expression of myr PKB reverted 
the severe developmental arrest of ∆Cam DN3 cells. The rescue of cellularity by PKB is not 
only restricted to the thymus but also prominent in the peripheral lymphoid organs (Fig.18). 
Although active PKB likely plays multiple roles in this interplay, one essential outcome of 
PKB’s action is downregulation of NFATc1 and NFATc3 activity in DN cells of ∆Cam mice 
(Figs. 27 & 28). Since in ∆Cam DN cells NFATc1 and NFATc2 levels were drastically 
increased, it seems that either their individual or combined continual activation essentially 
forbids TCRb chain rearrangement and hence pre-TCR formation. In this scenario, down-
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modulation of calcineurin-induced NFAT activity to appropriate levels by active PKB seems 
to be a prerequisite to proceed with RAG expression and recombinatorial processes similar to 
what was observed when ∆Cam DN cells were treated with the calcineurin inhibitor CsA.  
Calcineurin/NFAT signaling is known to have positive but also negative effects on 
gene transcription. For instance, negative regulation is found for the CDK4 gene, which is 
repressed under basal conditions by NFAT  (263). Although ∆Cam shuts off Rag and TCRb 
chain formation, it simultaneously at least partially signals in differentiation. This is obvious 
from our observations that despite presumably defective or incomplete pre-TCR signaling, 
∆Cam DN3 cells show up-regulation of the surface antigens CD2 and CD5 to levels 
characteristic for DN4 cells. Also ∆Cam DN cells express much higher levels of integrins 
LFA-1 and CD18 compared to control cells (Fig. 21B). Integrins are heterodimeric membrane 
glycoproteins, which are crucial in the regulation of haemopoiesis and thymic maturation, the 
direction and control of leukocyte adhesion and migration through tissues and in the 
development of inflammatory responses (274). Also, integrins, especially LFA-1 has been 
shown to be an important component of the immunological synapse that is formed between an 
APC and a T cell. The significance of the expression of such high levels of integrins in ∆Cam 
cells on the overall thymic phenotype needs further experimentation.  
 The severe block in DN3 to DN4 transition in ∆Cam mice does not seem to be 
because of increased cell death or reduced cell cycle. ∆Cam DN3 cells express very high 
levels of Bcl2 (Fig. 22A), an active anti-apoptotic molecule which should counteract enhanced 
cell death. Apoptosis analysis by annexinV staining further clarifies that fact (Fig. 22B). Also 
there was no significant alteration in the cell cycle status of ∆Cam DN cells compared to 
control mice or the double tg mice (Fig. 22C).  
Besides regulation of Rag and TCRb chain expression, continuous calcineurin/NFAT 
activation seems to have additional inhibitory effects since simultaneous expression of the 
fully rearranged OT1 TCR in ∆Cam mice only weakly restored differentiation of ∆Cam DN3 
cells to the DP stage (Fig. 25). Thus, we propose that independent of its role in regulating 
expression of pre TCR components, consistently high NFAT activity in DN cells exerts 
additional inhibitory effects thereby preventing DN3 to DN4 transition. In contrast, active 
PKB reverted thymocyte differentiation in ∆Cam mice almost to normality. This is achieved 
by controlling the inhibitory NFAT activities and presumably other critical regulators of 
DN3-DN4 transition, which may involve Notch (275, 276) or Wnt signalling (277, 278) or 
some other transcription factors. 
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It has become evident that signals from the pre-TCR bifurcate into those that regulate 
pre-T cell survival and proliferation and those that induce allelic exclusion, a process in which 
pre-TCR induced signals terminate further Vb-Db-Jb rearrangements (50, 55). To date only 
few molecules are known that are essential or mimic the ability of the pre TCR to terminate 
TCRb chain rearrangement, among them the adaptor molecule SLP76 (279) Notch 1 (275, 
276) and cytosolic PKD (280). Seen from this perspective, sustained levels of active NFAT in 
∆Cam mice seem to mimic those part(s) of pre-TCR signaling, which can initiate allelic 
exclusion and in ∆Cam mice therefore lead to premature shut-down of RAG expression and 
thus inhibition of TCRb chain formation. Rag expression is regulated at the transcriptional 
and post-transcriptional level. In T cells c-myb (281) and GATA3 (282) are among the few 
known transcription factors regulating Rag expression.  
PKB’s action on NFATs could be direct or indirect via some unknown target proteins. 
Database analysis for putative PKB phosphorylation sites on NFATs shows multiple 
phosphorylation sites spanning the calcineurin binding domain and the rel homology domain. 
We have previously shown that PKB co-precipitates with NFAT, indicating a physical 
association between the two molecules (233). Thus, PKB by directly interacting with NFAT 
might phosphorylate single or multiple serine residues critical for NFAT regulation. This 
seems to be true as invitro kinase assay shows multiple serine phosphorylation on NFATc1 by 
PKB (S.Y. Na, personal communication). Our data suggest that multiple serine 
phosphorylation by PKB interferes with proper NFAT activation either by interfering with 
calcineurin binding, inhibition of dephosphorylation of critical serine residues within the 
serine/proline rich region of NFAT or interference with proper exposure of the nuclear 
localization signal. These issues have to be clarified in future experiments.  
 
5.4  NFAT and PKB in tumor development and progression 
NFATs can act as positive and negative regulators of growth and proliferation (263, 264, 283, 
284). Upon activation and nuclear translocation they can upregulate or downregulate certain 
sets of gene expression depending on the situation and the context. After antigenic challenge 
T cells upregulate the expression of a number of genes, among these the well-characterized 
cytokine genes have been shown to be dependent on NFAT activation. NFATs also regulate 
the expression of Fas ligand (Fas L) gene once T cells are activated. After the withdrawl of 
the stimulus most of the activated T cells undergo apoptosis, a process known as activation 
induced cell death (AICD), in order to maintain T cell homeostasis. Thus, NFAT via 
upregulation of Fas L expression regulates uncontrolled T cell proliferation. This became 
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obvious in various NFAT single or double knock out mice, where T cells are hyperreactive 
and these mice develop various lymphoproliferative disorders (258, 259, 262). 
Further, it has been shown that NFAT can control cell cycle by repressing cyclin 
dependent kinase-4 (CDK4) gene expression (263). In this situation NFAT does not require 
AP-1 elements but only requires calcium-dependent signals to stabilize its association with 
the CDK4 promoter. A reduction in acetylation of histone H3 within the CDK4 promoter and 
a direct association of NFATc2 with histone deacetylase1 (HDAC1) has been observed. This 
suggests that NFATc2-dependent repression of the CDK4 promoter involves recruitment of 
an HDAC family member by NFATc2, which displaces E2F family members bound to the 
CDK4 promoter and modulates the acetylation status of the core histone H3 within the CDK4 
promoter (263). HDAC recruitment by NFAT may also contribute to silencing of many other 
genes.  
NFAT is also involved in regulation of various cyclins, which are the critical 
components of an ordered cell cycle progression. NFATc2-/- T cells are hyperproliferative and 
this is associated with an altered cell cycle control. These T cells overexpress cyclins A2, B1, 
E and F upon stimulation. Cyclins A2 and E are expressed at early and late stages of G1 phase 
of the cell cycle respectively. These two cyclins are implicated in propelling cells to enter into 
S phase, and cyclin A2 also promotes passage through S into G2 and M phases (285-287). It 
was reported that overexpression of cyclin E accelerates the G1/S phase transition, which 
results in the shortening of the cell cycle time (288, 289). This is further supported by the 
evidence from NFATc2-/- x NFATc3-/- double-knockout mice where it has been shown that the 
hyperproliferative response of CD4+ T cells is related to a shortened time of cell division 
(262). Further, cyclin A and cyclin E are overexpressed in some types of lymphoproliferative 
diseases, such as leukemias (289-291). Thus, dysregulated NFAT activity could have wide 
ranging effect on normal cellular functioning. Absence of NFAT nuclear activity could lead 
to uninhibited cellular proliferation and tumorigenesis.  
Evidence from a number of studies suggests that PKB perturbations play an important 
role in human malignancy. The first evidence concerning PKB’s involvement in cancers 
emerged when amplification and overexpression of PKBb was detected in human ovarian 
tumors and cell lines (120). Subsequent studies showed PKBb amplification and/or mRNA 
overexpression in 10-20% of human ovarian and pancreatic cancers (292, 293) and activation 
of the PKBb kinase in nearly 40% of ovarian cancers (294). Amplification of PKBa was 
observed in human gastric cancer (116) and PKBa kinase activity is often increased in 
prostate and breast cancers. Enhanced activity of PKBg was found in estrogen receptor- 
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deficient breast cancer and androgen-insensitive prostate cancer cell lines (295) suggesting 
that PKBg may contribute to the aggressiveness of steroid hormone-insensitive cancers.  
The involvement of PKB in diverse tumorigenic activities suggests that PKB 
activation alone might be sufficient to induce cancer. However, whereas overexpression of 
myristoylated forms of PKBa, PKBb, and PKBg are strongly oncogenic, wild-type forms of 
PKB are poorly transforming (124, 296). 
Overexpression and overactivity of PKB has also been found in malignancies of the 
lymphoid system. PKB tg mice (266) or mice lacking PTEN (247) where PKB activity is 
enhanced, develop lymphoma. Transgenic mice expressing myrPKB from a proximal Lck 
promoter develop thymomas at an early age, whereas transgenic mice expressing 
constitutively active Lck-PKBE40K develop primarily tumors of the peripheral lymphoid 
organs later in life (265). Thymomas arising from myrPKB transgenic mice express high 
levels of cyclin D3. The delayed appearance of myrPKB and PKBE40K-induced lymphomas 
suggests that tumor induction by constitutively active PKB transgenes is a multiple-step 
process.  
The ideal case to study whether PKB mediated lymphomas do show a dysregulation in 
NFAT activity and thereby probably exacerbates lymphoma progression is to analyze the 
lymphomas that develope in our myr PKB homozygous mice. Both NFAT deficient as well as 
PKB tg T cells show higher expression of various cyclins indicating alteration of cell cycle in 
both the situations. Thus, a common key to cell cycle dysregulation in the form of 
overexpression and overactive cyclins can be envisaged in absence of NFAT and in enhanced 
activity of PKB, which is exactly the situation in myr PKB transgenic mice. The fact became 
clear and consistent with our hypothesis and observation in PKB transgenic CD4+ T cells 
(Fig. 12A & B) so far, as CD4+ T cells from lymphoma show near absence of NFATc1 and 
NFATc2 in the nucleus (Fig. 29). Thus at least one mechanism responsible for PKB induced 
lymphomagenesis and progression seems to be a severe dysregulation of NFAT activation and 
nuclear translocation.  
Altogether, our study clearly defined the importance of a serine/threonine phosphatase, 
calcineurin, and a serine/threonine kinase, PKB, counteracting each other with NFAT as the 
common substrate and setting the signaling threshold to modulate early thymocyte 
development. Also we could prove PKB acting as an effective NFAT kinase could 
spectacularly rescue thymocyte development in ∆Cam mice by restoring Rag gene expression 
and subsequent TCRb gene rearrangement and functional TCRb chain expression. However, 
PKB is not enough to reverse it completely as still significantly higher percent of cells are 
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blocked at the DN3 stage. This could be due to additional problems in extra to lack of rag 
gene expression and b-selection or impairment of some other signaling molecules or 
pathways involved in early thymocyte development, which we are currently studying. 
PKB mediated negative regulation of NFAT activation, together with T cell 
hyperreactivity, enhanced cell cycle progression and the concomitant negative regulation of 
NFAT activation strengthen the point of PKB’s involvement in lymphoma or thymoma 
genesis and progression. This study will shed new lights on our understanding of PKB’s role 
in oncogenesis in the immune system in particular and in other systems in general.  
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Abbreviations 
 
Ab      antibody 
Ag      antigen 
APC      antigen presenting cell 
AP-1      activator protein 1 
7-AAD     7-Amino actinomycin D 
bHLH      basic helix-loop-helix 
BRCA-1     breast cancer susceptibility gene product 1 
BSS      balanced salt solution 
BSA      bovine serum albumin 
Ca2+      calcium ion 
cAMP      cyclic AMP 
CBP      cAMP binding protein 
CBA      cytokine bead array 
CD      cluster of differentiation 
CDK      cyclin dependent kinase 
CE      cytoplasmic extract 
CFSE  5-(and-6)-carboxyfluoresceinediacetate 
succinimidyl ester 
CIS      cytokine-induced Src homology 2 protein 
CK      casein kinase 
CN      calcineurin 
CsA      cyclosporin A 
cRPMI-1640     complete RPMI-1640 medium 
CREB      cAMP response element binding protein 
CTL      cytotoxic T-lymphocyte 
cTEC      cortical thymic epithelial cell 
DAPI      4’-6-Diamidino-2-phenylindole 
DBD      DNA binding domain 
∆Cam  calcineurin mutant, deleted autoinhibitory domain 
DC      dendritic cell 
DN      double negative 
DP      double positive 
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DTT      dithiothreitol 
ELISA      enzyme linked immunosorbent assay 
ERK      extracellular signal regulated kinase 
eNOS      endothelial nitric oxide synthase 
FACS      fluorescence activated cell sorting 
FCS      fetal calf serum 
FKHR      forkhead transcription factor 
FSC      forward scatter 
GATA3     GATA associated protein 3 
GNEF      guanine nucleotide exchange factor 
GSK3      glycogen synthase kinase 3 
HDAC      histonedeacetylase 
HEB      human E-box binding factor    
HSA      heat stable antigen 
hTERT     human telomerase catalytic subunit gene 
ic       intracellular  
Id      inhibitor of DNA binding 
IFN-g      interferon gamma 
IkB      inhibitor of NF-kB 
IKK      IkB kinase 
IL      interleukin 
ILK      integrin-linked kinase   
IP      immunoprecipitation 
JNK      c-jun N-terminal kinase 
ko      knock out 
LFA-1      leukocyte function antigen-1 
LEF-1      lymphocyte enhancer factor-1 
MHC      major histocompatibility complex 
mTOR      mammalian target of rapamycin 
NE      nuclear extract 
NES      nuclear export signal 
NFAT      nuclear factor of activated T cell 
NF-kB      nuclear factor kB 
NHR      NFAT homology region 
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NK cell     natural killer cell 
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